var title_f20_21_20816="Corneal abrasion";
var content_f20_21_20816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal abrasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear green stain in the central cornea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20816=[""].join("\n");
var outline_f20_21_20816=null;
var title_f20_21_20817="Distal radius measurements AP view";
var content_f20_21_20817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal radius measurements: AP view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three important measurements can be determined, using the AP view, to assess the distal radius. Radial inclination is the angle between one line drawn perpendicular to the long axis of the radius and a second line from the tip of the radial styloid to the central reference point (CRP). Radial height is the distance between two lines drawn perpendicular to the long axis of the radius: one through the distal tip of the radial styloid, the second through the CRP. Ulnar variance is the distance between this second line through the CRP and a line through the distal articular surface of the ulnar head. Measurements are often abnormal when a fracture of the distal radius is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20817=[""].join("\n");
var outline_f20_21_20817=null;
var title_f20_21_20818="Acromioclavicular joint injury (shoulder separation)";
var content_f20_21_20818=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acromioclavicular joint injury (shoulder separation) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/21/20818/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20818/contributors\" id=\"au7144\">",
"       Scott M Koehler, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/21/20818/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20818/contributors\" id=\"se7143\">",
"       Karl B Fields, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/21/20818/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20818/contributors\" id=\"de97\">",
"       Jonathan Grayzel, MD, FAAEM",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?20/21/20818?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SHOULDER SEPARATION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The acromioclavicular (AC) joint is formed by the cap of the shoulder (acromion) and the collar bone (clavicle). It is held together by taut ligaments (",
"     <a class=\"graphic graphic_figure graphicRef72771 \" href=\"UTD.htm?38/13/39122\">",
"      figure 1",
"     </a>",
"     ). The outer end of the clavicle is held in alignment with the acromion by the acromioclavicular ligaments and the coracoclavicular (CC) ligaments.",
"    </p>",
"    <p>",
"     The AC joint is strong, but its location makes it vulnerable to injury from trauma. Injury to the ligaments (also called shoulder separation) can occur as a result of a fall, direct blow, or hyperextension.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF SHOULDER SEPARATION INJURIES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Acromioclavicular injury",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acromioclavicular injury is labeled as a type I, II, III, IV, V, or VI, depending upon the extent of injury and number of ligaments involved. The type of injury can usually be determined with a physical examination and x-rays.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Type I injuries involve a sprain or partial tear of AC ligaments with no injury to the CC ligaments. This causes a tender AC joint that often has mild swelling. Type I sprains usually heal within a few weeks.",
"      </li>",
"      <li>",
"       Type II injuries involve a complete tear of the AC ligaments and a sprain or partial tear of the coracoclavicular (CC) ligaments. This causes a tender AC joint, often with significant swelling (",
"       <a class=\"graphic graphic_figure graphicRef67478 \" href=\"UTD.htm?5/45/5841\">",
"        figure 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Type III injuries involve a complete tear of both the AC and CC ligaments (",
"       <a class=\"graphic graphic_figure graphicRef55686 \" href=\"UTD.htm?11/29/11729\">",
"        figure 3",
"       </a>",
"       ). The AC joint will appear abnormal, although swelling may obscure the degree of injury. People with type III injuries have significant tenderness of the CC ligaments, which helps distinguish type III from type II injuries. Type III injuries often take longer to heal (several weeks to months).",
"      </li>",
"      <li>",
"       Type IV, V, VI injuries are the most severe. Treatment often requires surgery.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Other causes of shoulder pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Arthritis of the shoulder joint is a common cause of shoulder pain. Arthritis can occur after AC separation or as a natural part of the aging process. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/17/3345?source=see_link\">",
"      \"Patient information: Shoulder osteoarthritis treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other possible causes of shoulder pain include rotator cuff tendonitis or tears, scapulothoracic bursitis, biceps tendonitis, frozen shoulder (also called adhesive capsulitis), and others. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"      \"Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/36/25153?source=see_link\">",
"      \"Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"      \"Patient information: Bursitis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/21/37201?source=see_link\">",
"      \"Patient information: Frozen shoulder (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SHOULDER SEPARATION TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Pain relief",
"     </span>",
"     &nbsp;&mdash;&nbsp;If needed, a non-prescription pain medication such as acetaminophen (Tylenol&reg;), ibuprofen (eg, Advil&reg;, Motrin&reg;), or naproxen (eg, Aleve&reg;) can be taken. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .) No more than 3000 mg of acetaminophen is recommended per day. Anyone with liver disease or who drinks alcohol regularly should speak with his or her healthcare provider before taking acetaminophen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Type 1",
"     </span>",
"     &nbsp;&mdash;&nbsp;Type I injuries are best treated initially with rest, ice, and protection, often with an arm sling. Ice can be applied for 15 minutes every four to six hours as needed. Rest includes avoiding overhead reaching, reaching across the chest, lifting, leaning on the elbows, and sleeping directly on the shoulder.",
"    </p>",
"    <p>",
"     Range-of-motion exercises are recommended as soon as they can be tolerated.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Range-of-motion exercises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Range-of-motion exercises are recommended early in the recovery period. These exercises are intended to help maintain joint mobility and flexibility of the muscles and tendons in the shoulder. Pain should not exceed mild levels with any",
"     <span class=\"nowrap\">",
"      range-of-motion/flexibility",
"     </span>",
"     exercise. Anyone who feels sharp or tearing pain while stretching should stop exercising immediately and consult with a healthcare provider.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Weighted pendulum stretch &ndash; The weighted pendulum stretching exercise performs two functions:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Gently stretches the space in which the tendons pass to relieve pressure on the tendons",
"      </li>",
"      <li>",
"       Prevents the development of a frozen (stiff) shoulder",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This exercise can be started almost immediately after a shoulder injury. This exercise should be performed for five minutes once or twice per day. The exercise is performed as follows (",
"     <a class=\"graphic graphic_figure graphicRef50148 \" href=\"UTD.htm?12/37/12895\">",
"      figure 4",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Relax your shoulder muscles",
"      </li>",
"      <li>",
"       While standing or sitting, keep your arm vertical and close to your body (bending over too far may pinch the rotator cuff tendons)",
"      </li>",
"      <li>",
"       Allow your arm to swing forward to back, then side to side, then in small circles in each direction (no greater than 1 foot in any direction). Only minimal pain should be felt.",
"      </li>",
"      <li>",
"       Stretch the arm only (without added weight) for three to seven days. The difficulty of this exercise can be increased by adding 1 to 2 pounds (0.5 to 1 kg) each week and gradually increasing the diameter of the movements (not to exceed 18 to 24 inches or 45 to 60 cm )",
"      </li>",
"      <li>",
"       After a few weeks this exercise should be supplemented or replaced by other exercises to target specific areas of",
"       <span class=\"nowrap\">",
"        tightness/restriction.",
"       </span>",
"       The pendulum stretch may be recommended as a warm up for more localized flexibility exercises",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       strengthening exercises.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When performed correctly the pendulum exercise should not result in more than mild discomfort. If more pain is felt, consult a healthcare provider for instructions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Return to activity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people are able to return to full activities between three days and two weeks after an acromioclavicular joint injury. Athletes who use overhand motions (eg, those who play tennis and serve volleyball, baseball pitchers, American football quarterbacks) may require two to three weeks to return to full activity. Complete healing may take four to six weeks. Type I injuries generally heal well without an increased risk of reinjury.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Type II",
"     </span>",
"     &nbsp;&mdash;&nbsp;Type II injuries usually cause greater pain and swelling than type I injuries. Initial treatment may include rest, ice, pain medication, and three to seven days of shoulder immobilization in a sling. Range-of-motion exercises can be started when tolerable (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Range-of-motion exercises'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Strengthening exercises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Muscle strengthening exercises are necessary to improve shoulder muscle strength and help to prevent further injury. These exercises can often be started approximately one to two weeks after beginning the pendulum stretch exercises (described above), depending upon the level of pain.",
"    </p>",
"    <p>",
"     As pain improves, the level of difficulty of these exercises should be increased. Increased difficulty is necessary to improve muscle strength to a degree that reduces the risk of re-injury. Mild soreness is expected with these exercises, although pain should not continue for more than 24 hours. Sharp or severe pain during or after exercising may indicate a flare of the underlying problem; stop these exercises for a few days if this occurs.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Preparing for strengthening exercises &ndash; Once the swelling has decreased, the shoulder may be warmed with cardiovascular exercise or a warm pack and stretched with range-of-motion exercises before beginning strengthening exercises (see",
"       <a class=\"local\" href=\"#H8\">",
"        'Range-of-motion exercises'",
"       </a>",
"       above).",
"       <br/>",
"       <br/>",
"       Rest after stretching for two or three minutes, then perform 15 to 20 repetitions of each exercise slowly, holding for one to two seconds during each exercise. Flexible rubber tubing, a bungee cord, or a large rubber band can be used for each exercise.",
"      </li>",
"      <li>",
"       Scapular squeezes &ndash; Lie on your back with your knees bent and feet flat. Your arms should be straight out, six to 12 inches (15 to 30 cm) away from the side of your body, with palms facing upward. Keeping your low back flat against the ground, squeeze your shoulder blades downward and towards each other, towards the spine (",
"       <a class=\"graphic graphic_picture graphicRef65309 \" href=\"UTD.htm?37/24/38287\">",
"        picture 1",
"       </a>",
"       ). Make a conscious effort not to shrug your shoulders and keep the neck relaxed. You should feel the lower muscles between your shoulder blades contracting. Hold for five seconds and repeat 20 times. Do this exercise two to three times per day.",
"       <br/>",
"       <br/>",
"       The difficulty can be increased by performing it while sitting and then by holding a piece of tubing in each hand and pulling the hands apart while squeezing the shoulder blades, as described above.",
"      </li>",
"      <li>",
"       Outward rotation exercise &ndash; Hold your elbows at 90 degrees, close to your sides; holding a towel between your torso and the inside of your elbow will cue you to keep your elbow by your side. Hold one end of a rubber band in each hand and rotate the affected lower arm outward two or three inches, holding for five seconds (",
"       <a class=\"graphic graphic_picture graphicRef53514 \" href=\"UTD.htm?36/14/37089\">",
"        picture 2",
"       </a>",
"       ).",
"       <br/>",
"       <br/>",
"       Perform the exercise through all available pain-free ranges of motion. Keep the shoulder blades squeezed down and back while performing this exercise.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Return to activities",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a type II AC injury, most people are able to return to full activities when full range of motion and strength are regained, usually after two to four weeks. Complete healing generally requires several more weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Type III",
"     </span>",
"     &nbsp;&mdash;&nbsp;The majority of people with type III injuries can be managed with non-surgical treatment, including rest, ice, immobilization with a sling, and pain medication. A sling may be recommended for three to four weeks to aid in healing and to relieve pain.",
"    </p>",
"    <p>",
"     Range-of-motion and strengthening exercises can begin as soon as they are tolerable (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Range-of-motion exercises'",
"     </a>",
"     above and",
"     <a class=\"local\" href=\"#H11\">",
"      'Strengthening exercises'",
"     </a>",
"     above). The intensity of these exercises should be increased gradually, based upon pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Return to activities",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with a type III injury may return to normal activities between six and twelve weeks following injury, when full range of motion and strength are regained. Some people return to activity sooner or later, depending upon the demands of the specific activity.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Type IV, V, VI",
"     </span>",
"     &nbsp;&mdash;&nbsp;Type IV, V, and VI AC injuries are the most severe. People who have this type of injury should see a physician who specializes in bones and joints (an orthopedist). If nerves or muscles are compressed as a result of the injury, treatment is needed urgently to reduce the risk of long-term complications. Surgery is often recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804591540\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12025779\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/47/7923?source=see_link\">",
"      Patient information: Separated shoulder (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12025796\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/17/3345?source=see_link\">",
"      Patient information: Shoulder osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/36/25153?source=see_link\">",
"      Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"      Patient information: Bursitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/21/37201?source=see_link\">",
"      Patient information: Frozen shoulder (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=see_link\">",
"      Acromioclavicular joint injuries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Orthopaedic Surgeons",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://orthoinfo.aaos.org/\">",
"        file://orthoinfo.aaos.org/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Disease",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"        www.niams.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Physical Therapy Association",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.apta.org/\">",
"        www.apta.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Arthritis Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?20/21/20818/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?20/21/20818?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20818/abstract/1\">",
"      Renfree KJ, Wright TW. Anatomy and biomechanics of the acromioclavicular and sternoclavicular joints. Clin Sports Med 2003; 22:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20818/abstract/2\">",
"      Buss DD, Watts JD. Acromioclavicular injuries in the throwing athlete. Clin Sports Med 2003; 22:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20818/abstract/3\">",
"      Montellese P, Dancy T. The acromioclavicular joint. Prim Care 2004; 31:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20818/abstract/4\">",
"      Bradley JP, Elkousy H. Decision making: operative versus nonoperative treatment of acromioclavicular joint injuries. Clin Sports Med 2003; 22:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20818/abstract/5\">",
"      Spencer EE Jr. Treatment of grade III acromioclavicular joint injuries: a systematic review. Clin Orthop Relat Res 2007; 455:38.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f20_21_20818=[""].join("\n");
var outline_f20_21_20818=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SHOULDER SEPARATION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF SHOULDER SEPARATION INJURIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SHOULDER SEPARATION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/13/39122\" title=\"figure 1\">",
"           Normal shoulder lig PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/45/5841\" title=\"figure 2\">",
"           Type II AC joint sprain PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/29/11729\" title=\"figure 3\">",
"           Type III AC joint spr PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\" title=\"figure 4\">",
"           Pendulum stretch exercise PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/24/38287\" title=\"picture 1\">",
"           Scapular squeeze PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/14/37089\" title=\"picture 2\">",
"           Outward rotation PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f20_21_20819="Adult tachycardia algorithm";
var content_f20_21_20819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Adult tachycardia algorithm (with pulse): 2010 ACLS guidelines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 793px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CHF: congestive heart failure; ECG: electrocardiogram; IV: intravenous; J: joules; NS: normal (isotonic) saline; VT: ventricular tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Adult Advanced Cardiovascular Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20819=[""].join("\n");
var outline_f20_21_20819=null;
var title_f20_21_20820="Febuxostat: Patient drug information";
var content_f20_21_20820=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Febuxostat: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29668?source=see_link\">",
"     see \"Febuxostat: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7254933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Uloric&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11508520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Uloric&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gouty arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to febuxostat or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain when passing urine or blood in urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12173 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-2A6F391156-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20820=[""].join("\n");
var outline_f20_21_20820=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7254933\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11508520\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027572\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027574\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027573\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027578\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027579\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027581\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027576\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027577\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027582\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027583\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29668?source=related_link\">",
"      Febuxostat: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_21_20821="Labetalol: Patient drug information";
var content_f20_21_20821=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Labetalol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     see \"Labetalol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     see \"Labetalol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trandate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Labetalol&reg;;",
"     </li>",
"     <li>",
"      Labetalol Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Normodyne&reg;;",
"     </li>",
"     <li>",
"      Trandate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to labetalol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703309",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, poor electrical activity in the heart without a working pacemaker, very weak heart, or slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 12 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10785 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20821=[""].join("\n");
var outline_f20_21_20821=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186205\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186206\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019624\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019626\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019625\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019630\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019631\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019633\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019628\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019629\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019634\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019635\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=related_link\">",
"      Labetalol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=related_link\">",
"      Labetalol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_21_20822="Topotecan: Pediatric drug information";
var content_f20_21_20822=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topotecan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"    see \"Topotecan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/34/5670?source=see_link\">",
"    see \"Topotecan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hycamtin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hycamtin&reg;;",
"     </li>",
"     <li>",
"      Topotecan For Injection;",
"     </li>",
"     <li>",
"      Topotecan Hydrochloride For Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Camptothecin",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Topoisomerase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"      see \"Topotecan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Individual Protocols:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric solid tumors: 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (range: 0.75-1.9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) for 3 days as a continuous infusion, repeated every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single-agent therapy for refractory solid tumors or hematologic malignancies: 2.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily for 5 days of a 21 day course.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combination therapy for solid tumors: 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days every 21 days in combination with cyclophosphamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Intermittent infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ovarian cancer and small cell lung cancer: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily for 5 days followed by a 16 day rest period; repeat course every 21 days for 4 courses. If neutrophil count falls to &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or if platelets decrease to &lt;25,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , reduce dose by 0.25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for subsequent courses. Alternatively for severe neutropenia, administer G-CSF 24 hours after completion of topotecan infusion following subsequent courses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cervical cancer: 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily on days 1, 2, and 3; repeat every 21 days in combination with cisplatin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Continuous infusion: Ovarian cancer: 0.2-0.7mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 7-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Small cell lung cancer: 2.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days; repeat every 21 days. If patient vomits after dose is administered, do not give a replacement dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Reduce dosage by 50% or by 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Insufficient data available to recommend dosage adjustment guidelines",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Reduce dose to 1.8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Insufficient data available for dosing recommendation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Bilirubin 1.5-10 mg/dL: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Bilirubin &gt;1.5 mg/dL: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ovarian and small cell lung cancer: Dosage adjustment for hematological effects: Severe neutropenia or platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Reduce dose to 1.25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycles (may consider G-CSF support [beginning on day 6] prior to instituting dose reduction for neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cervical cancer: Severe febrile neutropenia (ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with temperature of 38&deg; C) or platelet count &lt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Reduce topotecan to 0.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycles (may consider C-CSF support [beginning on day 4] prior to instituting dose reduction for neutropenic fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For neutropenic fever despite G-SCF use, reduce dose to 0.45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycles.",
"     <b>",
"      Note:",
"     </b>",
"     Cisplatin may also require dose adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Small cell lung cancer: Severe neutropenia (neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     associated with fever or infection or lasting &gt;7 days) or prolonged neutropenia (neutrophils &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     to &le;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     lasting beyond day 21) or platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or grades 3/4 diarrhea: Reduce dose to 1.9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for subsequent cycles (may consider same dosage reduction for grade 2 diarrhea if clinically indicated.)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hycamtin&reg;: 0.25 mg, 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hycamtin&reg;: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 1 mg/mL (4 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: May administer by intermittent infusion over 30 minutes or by continuous infusion at a final concentration not to exceed 0.5 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May administer with or without food. Swallow capsule whole; do not crush, chew, or divide capsule.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F229337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Carboplatin, cimetidine, cisplatin, cyclophosphamide, doxorubicin, etoposide, gemcitabine, granisetron, ifosfamide, methylprednisolone sodium succinate, metoclopramide, ondansetron, oxaliplatin, paclitaxel, palonosetron, prochlorperazine edisylate, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dexamethasone sodium phosphate, fluorouracil, mitomycin, pemetrexed.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ticarcillin/clavulanate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store capsules in refrigerator. Store intact vials containing lyophilized powder at room temperature; protect from light. Reconstituted solution for injection is stable for 24 hours at room temperature or up to 7 days if refrigerated; if topotecan is further diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS, it is stable for 24 hours at room temperature or up to 7 days under refrigeration. Do",
"     <b>",
"      not",
"     </b>",
"     dilute in alkaline solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ovarian cancer after failure of first-line chemotherapy; second-line treatment of small cell lung cancer; cervical cancer (FDA approved in adults); has also been used in nonsmall cell lung cancer, myelodysplastic syndrome, pediatric solid tumor, including sarcoma and neuroblastoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F229339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hycamtin&reg; may be confused with Mycamine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Topotecan may be confused with irinotecan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F229336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia (reversible), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, nausea, obstruction, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, neutropenia (nadir 8-11 days; recovery &lt;21 days), neutropenic fever/sepsis, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bun increased, liver enzymes increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, anaphylactoid reactions, angioedema, bleeding (severe, associated with thrombocytopenia), dermatitis (severe), extravasation (inadvertent), interstitial lung disease (ILD), neutropenic colitis, pancytopenia, pruritus (severe)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to topotecan or any component; severe bone marrow depression (patients with baseline neutrophil counts &lt;1,500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ); pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with renal or hepatic impairment; modify dosage in patients with renal impairment. Inadvertent extravasation is generally mild (although severe cases have been reported). Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . The dose-limiting toxicity is bone marrow suppression, primarily neutropenia (may also cause thrombocytopenia and anemia); monitor bone marrow function. Neutropenia is not cumulative over time. Should only administer to patients with adequate bone marrow reserves, baseline neutrophils at least 1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet counts at least 100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Topotecan-induced neutropenia may lead to neutropenic colitis; should be considered in patients presenting with neutropenia, fever, and abdominal pain. Severe diarrhea, including cases requiring hospitalization, have been reported with oral topotecan; dose adjustment may be needed. May cause fetal harm when administered to pregnant women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Interstitial lung disease (ILD) (with fatalities) has been reported; monitor for signs/symptoms (eg, dyspnea, fever, cough, hypoxia) and discontinue use in patients with confirmed ILD. Risk factors for ILD include a history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and the use of colony-stimulating factors or medication with pulmonary toxicity. Monitor pulmonary symptoms (cough, fever, dyspnea, and/or hypoxia) and discontinue if ILD is diagnosed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCRP/ABCG2 Inhibitors: May increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Filgrastim: May enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Platinum Derivatives: May enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F229279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies found embryotoxicity, fetotoxicity, reduced fetal body weight, and teratogenicity including eye, brain, skull, and vertebrae malformations. May cause fetal harm in pregnant women. Women of childbearing potential should use effective contraception to prevent pregnancy during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count; renal and hepatic function tests; blood pressure during infusion; monitor for signs and symptoms of interstitial lung disease",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topoisomerase I inhibitor which stabilizes the covalent complex between topoisomerase I and DNA preventing religation of DNA single-strand breaks resulting in interference with DNA replication, RNA transcription, and DNA repair.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 87.3 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; distributes into tissues and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes pH dependent hydrolysis of its active lactone moiety to yield a relatively inactive open-ring hydroxy acid form in plasma; active metabolite, N-demethylated topotecan, formed in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-3 hours; 5 hours with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Urine: 51%; feces: 18%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Urine: 20%; feces: 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Topotecan plasma clearance is 24% higher in males than in female patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     No previous radiation therapy and no bone marrow involvement: 12.2 &plusmn; 3.5 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     (range: 6.8-17.4 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Previous radiation without bone marrow involvement: 9.8 &plusmn; 4.1 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     (range: 4.8-17.4 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 6.5-30 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/34/5670?source=see_link\">",
"      see \"Topotecan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform physician of persistent fever, chills, bruising, bleeding, abdominal pain, diarrhea, yellowing of eyes or skin, or pain at infusion site. Avoid alcohol; may cause fatigue and impair ability to perform activities requiring mental alertness or physical coordination. Topotecan may cause birth defects; contraceptive measures are recommended during therapy. If vomiting occurs after oral topotecan dose, do not take replacement dose.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC (nadir): 8-11 days; recovery: 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrophils (nadir): 12 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets (nadir): 15 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Furman WL, Stewart CF, Kirstein M, et al, &ldquo;Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study,&rdquo;",
"      <i>",
"       J of Clin Oncology",
"      </i>",
"      , 2002, 20(6):1617-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20822/abstract-text/11896112 /pubmed\" id=\"11896112 \" target=\"_blank\">",
"        11896112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santana VM, Zamboni WC, Kirstein MN, et al, &ldquo;A Pilot Study of Protracted Topotecan Dosing Using a Pharmacokinetically Guided Dosing Approach in Children With Solid Tumors,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2003, 9(2):633-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20822/abstract-text/12576429/pubmed\" id=\"12576429\" target=\"_blank\">",
"        12576429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saylors RL 3rd, Stine KC, Sullivan J, et al, &ldquo;Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(15):3463-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20822/abstract-text/11481351/pubmed\" id=\"11481351\" target=\"_blank\">",
"        11481351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walterhouse DO, Lyden ER, Breitfeld PP, et al, &ldquo;Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children's Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(8):1398-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20822/abstract-text/15007087/pubmed\" id=\"15007087\" target=\"_blank\">",
"        15007087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells RJ, Reid JM, Ames MM, et al, &ldquo;Phase I Trial of Cisplatin and Topotecan in Children With Recurrent Solid Tumors: Children's Cancer Group Study 0942,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2002, 24(2):89-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20822/abstract-text/11990712/pubmed\" id=\"11990712\" target=\"_blank\">",
"        11990712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13005 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-A0D016103C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20822=[""].join("\n");
var outline_f20_21_20822=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708912\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229294\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229295\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050402\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050394\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229271\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229256\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050405\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229337\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050397\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050404\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229339\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229336\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050408\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050393\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050392\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300156\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229264\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229267\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229279\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050401\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050391\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050407\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050399\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050409\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=related_link\">",
"      Topotecan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/34/5670?source=related_link\">",
"      Topotecan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_21_20823="Large for gestational age newborn";
var content_f20_21_20823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Large for gestational age newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/21/20823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20823/contributors\">",
"     George T Mandy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/21/20823/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20823/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/21/20823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20823/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/21/20823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who are born large for gestational age (LGA), especially full term or post term infants, are at risk for perinatal morbidity and potentially long-term metabolic complications.",
"   </p>",
"   <p>",
"    The pathogenesis, epidemiology, risk factors, complications, and management of infants born LGA will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339470\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, LGA is defined as a birth weight greater than the 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age. However, it has been suggested that the definition be restricted to infants with birth weights greater than the 97th percentile (2 standard deviations above the mean) as this more accurately describes infants who are at greatest risk for perinatal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Using a national reference based on single live births in the United States, infants born at 40 weeks gestation at the 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile had birth weights greater than 4000 g and those at the 97",
"    <sup>",
"     th",
"    </sup>",
"    percentile greater than 4400 g [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrosomia refers to excessive intrauterine growth beyond a specific threshold regardless of gestational age. This condition usually is defined as a birth weight greater than 4000 or 4500 g. The American College of Obstetricians and Gynecologists supports use of the 4500 g threshold for diagnosis of macrosomia because morbidity increases sharply beyond this weight.",
"   </p>",
"   <p>",
"    A grading system for macrosomia has been proposed based on birth weight (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=see_link&amp;anchor=H2#H2\">",
"     \"Fetal macrosomia\", section on 'Definition'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 1 &ndash; 4000 to 4499 g",
"     </li>",
"     <li>",
"      Grade 2 &ndash; 4500 to 4999 g",
"     </li>",
"     <li>",
"      Grade 3 &ndash; &gt;5000 g",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Term infants who are appropriate for gestational age (AGA) have birth weights between 2500 and 3999 g.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68825427\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among liveborn infants in the United States born in 2008, the incidence of LGA based on the above grades of macrosomia is 6.6, 0.9, and 0.1 percent for birth weights of 4000 to 4499 g, 4500 to 4999 g, and &gt;5000 g, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/4\">",
"     4",
"    </a>",
"    ]. The birth rates for all three grades of LGA have declined in the United States from 1990 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/4\">",
"     4",
"    </a>",
"    ]. However, in other countries (eg, Sweden and Australia), the reported incidence of LGA births has increased [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In these countries, the rise in proportion of neonates born LGA was thought to be due to a decrease exposure to prenatal smoking, and increases in maternal age and weight, and gestational diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the mechanisms that control fetal weight gain and growth are poorly understood, excessive fetal growth appears to be due to increased delivery of nutrients to the fetus, which is",
"    <span class=\"nowrap\">",
"     influenced/caused",
"    </span>",
"    by genetic and intrauterine environmental factors, or a combination of the two.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic factors &ndash; In a number of genetic syndromes, macrosomia is a characteristic feature [",
"      <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There is ethnic variability in the incidence of LGA infants.",
"     </li>",
"     <li>",
"      Familial trait &ndash; Mothers who were LGA are more likely to deliver a LGA infant than mothers who were AGA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrauterine environmental factors &ndash; LGA infants are more likely to be delivered to mothers who are obese, have diabetes, and those with gestational weight gain greater than 40 lbs. These maternal conditions result in excessive delivery of nutrients to the fetus that contributes to increased fetal growth.",
"     </li>",
"     <li>",
"      Epigenetic factors &ndash; Limited data suggest that placental epigenetic alterations may contribute to increased fetal growth. These changes include methylation of the placental glucocorticoid receptor and upregulation of the placental growth",
"      <span class=\"nowrap\">",
"       hormone/chorionic",
"      </span>",
"      somatomammotropin genes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68825740\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68825662\">",
"    <span class=\"h3\">",
"     Genetic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several genetic disorders are characterized by early excessive growth resulting in an LGA infant. They include Beckwith-Wiedemann syndrome, Simpson-Golabi-Behmel syndrome, Sotos syndrome, Weaver syndrome, and Berardinelli lipodystrophia (",
"    <a class=\"graphic graphic_table graphicRef62116 \" href=\"UTD.htm?19/35/20027\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68825770\">",
"    <span class=\"h3\">",
"     Race and ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Racial and ethnic factors influence birth weight. In a study from the United States that included all term singleton live births from 1995 to 1997, mothers who were white, American Indian, or Samoan were disproportionately overrepresented in the group with LGA offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, black mothers were underrepresented. In another report of mothers with gestational diabetes, macrosomia occurred significantly more often in Latino than black infants (50 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68825693\">",
"    <span class=\"h2\">",
"     Maternal factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Maternal diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrosomia is common in infants of diabetic mothers (IDM), especially when maternal diabetes is poorly controlled. Excessive delivery of nutrients to the fetus results in fetal hyperglycemia and hyperinsulinemia, and increased growth. In IDMs, macrosomia is also associated with disproportionate growth with an increased ponderal index that results in higher chest-to-head and shoulder-to head ratios, higher body fat, and thicker upper extremity skinfolds compared with LGA offspring of nondiabetic mothers (",
"    <a class=\"graphic graphic_picture graphicRef54212 \" href=\"UTD.htm?28/8/28805\">",
"     picture 1",
"    </a>",
"    ). This disproportionate macrosomia increases the risk of birth injuries, especially shoulder dystocia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link&amp;anchor=H13#H13\">",
"     \"Infant of a diabetic mother\", section on 'Macrosomia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link&amp;anchor=H6#H6\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\", section on 'Macrosomia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Maternal prepregnancy weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of an LGA offspring increases in a linear fashion as the prepregnancy maternal weight rises. As a result, the highest risk of delivering a LGA infant occurs in obese mothers. This relationship is independent of the increased prevalence of gestational diabetes in obese women. The evidence for the effect of maternal prepregnancy weight on birth weight is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link&amp;anchor=H32#H32\">",
"     \"The impact of obesity on fertility and pregnancy\", section on 'Macrosomia and subsequent weight'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Excessive maternal weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive maternal weight gain during pregnancy is associated with macrosomia. Women with normal prepregnancy body mass index who gained more than 35 lbs (15.9 kg) had an almost 2.5 times greater risk of delivering a LGA infant compared with mothers who gained between 25 and 35 lbs (11.3 and 15.9 lbs) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/11\">",
"     11",
"    </a>",
"    ]. The amount of weight gain associated with a LGA birth is lower in women who are overweight or obese as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link&amp;anchor=H32#H32\">",
"     \"The impact of obesity on fertility and pregnancy\", section on 'Macrosomia and subsequent weight'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link&amp;anchor=H4#H4\">",
"     \"Weight gain and loss in pregnancy\", section on 'Recommendations for weight gain during pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link&amp;anchor=H20254135#H20254135\">",
"     \"Weight gain and loss in pregnancy\", section on 'Overweight and obese women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that are associated with the birth of LGA infant include multiparity, advanced maternal age, post term pregnancy, male infant, birth of a previous LGA infant, and maternal birth weight greater than 4000 g (",
"    <a class=\"graphic graphic_table graphicRef79202 \" href=\"UTD.htm?3/51/3899\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NEONATAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal morbidity is greater in LGA infants (birth weights above 4000 g) compared with full term AGA infants (birth weights between 2500 to 3999 g). In addition, morbidity increases as the birth weight increases above 4000 g.",
"   </p>",
"   <p>",
"    This was best illustrated in a study that analyzed data that included all singleton live births in the United States from 1995 to 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/2\">",
"     2",
"    </a>",
"    ]. Logistic regression analysis demonstrated that the risk of several neonatal complications was greater in LGA infants compared with infants who were AGA (birth weight 3000 to 3999 g), and the frequency increased with increasing severity of macrosomia as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to AGA infants, the risk of birth injuries was twofold, threefold, and fourfold greater for infants with grade 1 (birth weight between 4000 and 4499 g), grade 2 (birth weight between 4500 and 4999 g), and grade 3 (birth weight &gt;5000 g) macrosomia, respectively.",
"     </li>",
"     <li>",
"      Mechanical ventilation for more than 30 minutes duration was 1.19 (95% CI 1.14-1.23), 1.85 (95% CI 1.73-1.99), and 3.96 (95% CI 3.45-4.55) times greater for infants with grades 1, 2, and 3 macrosomia, respectively.",
"     </li>",
"     <li>",
"      The risk of a five-minute Apgar score lower than three was 1.3 (95% CI 1.21-1.39), 2.0 (95% CI 1.76-2.29), and 5.2 (95% CI times 4.09-6.62) greater for infants with grades 1, 2, and 3 macrosomia, respectively.",
"     </li>",
"     <li>",
"      The risk of respiratory distress syndrome (referred to as hyaline membrane disease) was 1.15 (95% CI 1.1-1.22), 1.84 (95% CI 1.68-2.01), and 3.7 (95% CI 3.11-4.4) times greater for infants with grades 1, 2, and 3 macrosomia, respectively.",
"     </li>",
"     <li>",
"      The risk of meconium aspiration was 1.28 (95% CI 1.23-1.34), 1.65 (95% CI 1.52-1.79), and 2.61 (95% CI 2.15-3.16) times greater for infants with grades 1, 2, and 3 macrosomia, respectively.",
"     </li>",
"     <li>",
"      Neonatal mortality was only increased in infants with grade 3 macrosomia and was 2.69 (95% CI 1.91-3.8) times greater than the mortality rate in AGA infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Macrosomia also is associated with significant maternal morbidity including an increased likelihood of cesarean delivery, severe postpartum hemorrhage, and vaginal lacerations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=see_link\">",
"     \"Fetal macrosomia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=see_link&amp;anchor=H19#H19\">",
"     \"Intrapartum management and outcome of shoulder dystocia\", section on 'Maternal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased morbidity seen in LGA infants results in a higher utilization of neonatal intensive care compared with AGA infants as illustrated by a study from the Arizona Neonatal Intensive Care Program (NICP) of infants born between 1994 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/12\">",
"     12",
"    </a>",
"    ]. In this study, LGA infants with birth weights &gt;4000 g were more likely to be enrolled in the NICP (criteria included admission to a NICU for a prolonged stay [&gt;72 hours], readmission to a neonatal intensive care unit [NICU], or transport to a NICU) compared with AGA infants with birth weights between 2500 and 3999 g (2.7 versus 2.1 percent). The four most common diagnoses in LGA infants, which accounted for 53 percent of the admission diagnoses, were respiratory distress (19 percent), transient tachypnea of the newborn infant (16 percent), hypoglycemia (9 percent), and meconium aspiration (9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Birth injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrosomia predisposes to shoulder dystocia and birth injury, including brachial plexus injury and clavicular fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ]. As previously noted, the risk of birth injury increases with the severity of macrosomia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the rate of birth injury for LGA infants is greater in vaginal compared with cesarean deliveries. In one large case series, birth injury was three times more likely when LGA infants (birth weight 4500 to 5000 g) were the product of vaginal compared with cesarean delivery (9.3 versus 2.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neonatal complications of shoulder dystocia are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=see_link&amp;anchor=H18#H18\">",
"     \"Intrapartum management and outcome of shoulder dystocia\", section on 'Infant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1891580\">",
"    <span class=\"h2\">",
"     Respiratory distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, LGA infants are more likely to develop respiratory distress than AGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. This is primarily due to the increased risk of respiratory distress syndrome, especially in infants of diabetic mothers who are more likely to be delivered prematurely. The higher incidence of cesarean deliveries in LGA infants appears to increase the risk of transient tachypnea of the newborn. In addition, meconium aspiration is a common respiratory complication in LGA infants, perhaps due to the increased risk of perinatal depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link&amp;anchor=H16#H16\">",
"     \"Infant of a diabetic mother\", section on 'Respiratory distress'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=see_link&amp;anchor=H3#H3\">",
"     \"Transient tachypnea of the newborn\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;LGA infants have increased intrauterine exposure to excessive nutrients, especially glucose, which may result in hyperinsulinemia, increased utilization of oxygen and glucose, and oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. These abnormalities may lead to perinatal complications including hypoglycemia, polycythemia, and asphyxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;LGA infants can develop hypoglycemia when the placental supply of glucose is interrupted at birth. In a report based upon data from the Netherlands Perinatal Registry from 1997 to 2002, the incidence of hypoglycemia was about 19 and 15 percent in all LGA infants and in LGA infants of nondiabetic mothers, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/17\">",
"     17",
"    </a>",
"    ]. Seizures due to hypoglycemia occurred in 0.3 percent of all LGA infants and in 0.2 percent of LGA infants without maternal diabetes. In another large case series of 887 German LGA infants (defined as a birth weight &gt;90",
"    <sup>",
"     th",
"    </sup>",
"    percentile) who were tested for hypoglycemia, 16 percent had hypoglycemia (blood glucose level &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    during the first 24 hours of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link&amp;anchor=H8#H8\">",
"     \"Neonatal hypoglycemia\", section on 'Increased glucose utilization due to hyperinsulinism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link&amp;anchor=H179706548#H179706548\">",
"     \"Neonatal hypoglycemia\", section on 'Who should be evaluated'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia occurs more frequently in LGA infants of both diabetic and nondiabetic mothers compared with AGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/19\">",
"     19",
"    </a>",
"    ]. The mechanism of polycythemia is thought to be due to an increased production of erythropoietin, which results from fetal hypoxia caused by the increased oxidative demands associated with hyperglycemia and hyperinsulinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link\">",
"     \"Neonatal polycythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Perinatal asphyxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrosomic infants are at increased risk for perinatal asphyxia, especially infants of diabetic mothers. Indirect evidence of the increased risk of perinatal asphyxia in LGAs is the higher frequency of low Apgar scores in LGA compared with AGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/1,2,13,20\">",
"     1,2,13,20",
"    </a>",
"    ]. Contributing factors are thought to be increased intrauterine oxygen utilization due to fetal hyperglycemia and hyperinsulinemia especially in infants of diabetic mothers, and complications of delivery related to shoulder dystocia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link&amp;anchor=H12#H12\">",
"     \"Infant of a diabetic mother\", section on 'Perinatal asphyxia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=see_link&amp;anchor=H18#H18\">",
"     \"Intrapartum management and outcome of shoulder dystocia\", section on 'Infant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor congenital anomalies are more common in LGA than AGA infants. This was evaluated in a retrospective case-control study of more than two million births in Latin America, of which 1800 of 31,897 infants with congenital anomalies were LGA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/21\">",
"     21",
"    </a>",
"    ]. The most common anomalies associated with macrosomia included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Talipes calcaneovalgus and hip subluxation caused by intrauterine deformation",
"     </li>",
"     <li>",
"      Hydrocephaly and combined angiomatoses resulting in increased body mass and fluid, and thus increased birth weight",
"     </li>",
"     <li>",
"      Non-brown pigmented nevi",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1891644\">",
"    <span class=\"h2\">",
"     Neonatal mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although neonatal mortality is higher in LGA than in AGA infants, it may be greater in only the most severe grade of macrosomia. As noted above, in a study of all singleton term live births between 1995 and 1997, the neonatal mortality rate was only higher in infants born with grade 3 macrosomia (birth weights &gt;5000 g) compared with AGA infants (adjusted odds ratio 2.69, 95% CI 1.91-3.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar results were noted in a Canadian study that reported more than a twofold increased risk of deaths in term infants with birth weights greater than 97th percentile compared with AGA term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1891711\">",
"    <span class=\"h1\">",
"     NEONATAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal management of LGA infants includes screening and treating complications associated with macrosomia, determining, if possible, the etiology of increased growth, and providing routine newborn care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to delivery, an assessment of the need for neonatal resuscitation is made based on the gestational age, anticipated birth weight, presence of a congenital anomaly or labor complications, the mode of delivery (eg, cesarean delivery), and maternal history. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H2#H2\">",
"       \"Neonatal resuscitation in the delivery room\", section on 'Anticipation of resuscitation need'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immediately after delivery, routine neonatal care is provided that includes drying, clearing the airway of secretions, maintaining warmth, and a rapid assessment of the infant&rsquo;s clinical status based on respiratory effort, tone, heart rate, and an examination to identify any major congenital anomaly or genetic syndrome. The need for further intervention is based on this initial evaluation. If the infant does not require additional resuscitation, the infant should be given to the mother for skin-to-skin care and initiation of breastfeeding in the delivery room. LGA infants should be fed as quickly as possible after delivery to avoid hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H7#H7\">",
"       \"Neonatal resuscitation in the delivery room\", section on 'Overview of resuscitative steps'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of the routine management of the healthy newborn infant\", section on 'Delivery room care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Further evaluation following transition from the delivery room includes a comprehensive examination to identify any underlying genetic syndrome (",
"      <a class=\"graphic graphic_table graphicRef62116 \" href=\"UTD.htm?19/35/20027\">",
"       table 1",
"      </a>",
"      ), any evidence of birth trauma (eg, perinatal depression, brachial plexus injury, or clavicular fracture), or congenital defects. (See",
"      <a class=\"local\" href=\"#H68825662\">",
"       'Genetic syndromes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Birth injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Congenital anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory screening for hypoglycemia and polycythemia should be performed within the first hours following birth. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hypoglycemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Polycythemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link&amp;anchor=H16#H16\">",
"       \"Neonatal hypoglycemia\", section on 'Evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link&amp;anchor=H14#H14\">",
"       \"Neonatal polycythemia\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there are no significant complications that require further intervention, routine newborn care should be provided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link\">",
"       \"Overview of the routine management of the healthy newborn infant\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POTENTIAL LONG-TERM EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals of both diabetic and nondiabetic mothers who were born LGA may have long-term metabolic effects that increase the risk of obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20823/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Ongoing studies will be needed to see whether effects increase the incidence of adult diseases such as obesity, diabetes, and cardiovascular disease.",
"   </p>",
"   <p>",
"    The long-term effect of being born LGA on neurodevelopmental outcome is unknown. There are limited data that suggest infants born to mothers with poorly controlled diabetes may be at risk for developmental abnormalities; however, the quality of evidence is poor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link&amp;anchor=H713946#H713946\">",
"     \"Infant of a diabetic mother\", section on 'Neurodevelopmental outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1892632\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who are born large for gestational age (LGA), especially full term or post term infants, are at risk for perinatal morbidity and potentially long-term metabolic complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although LGA has been defined as a birth weight greater than the 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile, it has been proposed that a higher threshold of at least 97",
"      <sup>",
"       th",
"      </sup>",
"      percentile be used because this more accurately describes infants who are at greatest risk for perinatal morbidity and mortality. At 40 weeks gestation, infants at the 90",
"      <sup>",
"       th",
"      </sup>",
"      and 97",
"      <sup>",
"       th",
"      </sup>",
"      percentile weigh more than 4000 or 4400 g. The American College of Obstetricians and Gynecologists uses a 4500 g threshold for the diagnosis of macrosomia (excessive fetal growth). (See",
"      <a class=\"local\" href=\"#H339470\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States (US), the incidence of LGA for infants born at 40 weeks gestation is 6.6, 0.9, and 0.1 percent based on birth weights of 4000 to 4499 g, 4500 to 4999 g, and &gt;5000 g, respectively. Although the incidence of LGA has declined in the US, it appears to be increasing in other countries due to increases in maternal age and weight, gestational diabetes, and decreases in maternal smoking. (See",
"      <a class=\"local\" href=\"#H68825427\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excessive fetal growth (macrosomia) resulting in LGA is associated with genetic factors (syndromes such as Beckwith-Wiedemann (",
"      <a class=\"graphic graphic_table graphicRef62116 \" href=\"UTD.htm?19/35/20027\">",
"       table 1",
"      </a>",
"      )), intrauterine environmental factors (eg, maternal diabetes and obesity, excessive maternal weight gain), and other maternal factors, such as advanced maternal age and multiparity (",
"      <a class=\"graphic graphic_table graphicRef79202 \" href=\"UTD.htm?3/51/3899\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal complications are more frequent in infants who are LGA compared with those who are born appropriate for gestational age (AGA). Complications associated with LGA include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Birth injuries (brachial plexus injury, perinatal asphyxia, and clavicular injury) primarily due to shoulder dystocia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Birth injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory distress generally due to respiratory distress syndrome, transient tachypnea of the newborn, or meconium aspiration. (See",
"      <a class=\"local\" href=\"#H1891580\">",
"       'Respiratory distress'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoglycemia. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polycythemia. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Polycythemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal mortality appears to be increased only in LGA term infants with birth weights &gt;5000 g compared with AGA term infants. (See",
"      <a class=\"local\" href=\"#H1891644\">",
"       'Neonatal mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of a LGA infant includes screening and treating any complication associated with macrosomia, determining, if possible, the etiology of macrosomia, and providing routine newborn care. We recommend that in the first few hours following delivery, laboratory evaluation include measurement of blood glucose and hematocrit (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Individuals of both diabetic and nondiabetic mothers who were born LGA may have long-term metabolic effects that increase the risk of obesity and insulin resistance. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Potential long-term effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/1\">",
"      Xu H, Simonet F, Luo ZC. Optimal birth weight percentile cut-offs in defining small- or large-for-gestational-age. Acta Paediatr 2010; 99:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/2\">",
"      Boulet SL, Alexander GR, Salihu HM, Pass M. Macrosomic births in the united states: determinants, outcomes, and proposed grades of risk. Am J Obstet Gynecol 2003; 188:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/3\">",
"      Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996; 87:163.",
"     </a>",
"    </li>",
"    <li>",
"     Martin JA, Hamilton BE, Sutton PD, et al. Births: Final Data for 2006. Natl Vital Stat Rep 2010; 59:1. file://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_01.pdf (Accessed on October 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/5\">",
"      Surkan PJ, Hsieh CC, Johansson AL, et al. Reasons for increasing trends in large for gestational age births. Obstet Gynecol 2004; 104:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/6\">",
"      Hadfield RM, Lain SJ, Simpson JM, et al. Are babies getting bigger? An analysis of birthweight trends in New South Wales, 1990-2005. Med J Aust 2009; 190:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/7\">",
"      M&auml;nnik J, Vaas P, Rull K, et al. Differential expression profile of growth hormone/chorionic somatomammotropin genes in placenta of small- and large-for-gestational-age newborns. J Clin Endocrinol Metab 2010; 95:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/8\">",
"      Freemark M. Placental hormones and the control of fetal growth. J Clin Endocrinol Metab 2010; 95:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/9\">",
"      Filiberto AC, Maccani MA, Koestler D, et al. Birthweight is associated with DNA promoter methylation of the glucocorticoid receptor in human placenta. Epigenetics 2011; 6:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/10\">",
"      Homko CJ, Sivan E, Nyirjesy P, Reece EA. The interrelationship between ethnicity and gestational diabetes in fetal macrosomia. Diabetes Care 1995; 18:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/11\">",
"      DeVader SR, Neeley HL, Myles TD, Leet TL. Evaluation of gestational weight gain guidelines for women with normal prepregnancy body mass index. Obstet Gynecol 2007; 110:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/12\">",
"      Gillean JR, Coonrod DV, Russ R, Bay RC. Big infants in the neonatal intensive care unit. Am J Obstet Gynecol 2005; 192:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/13\">",
"      Spellacy WN, Miller S, Winegar A, Peterson PQ. Macrosomia--maternal characteristics and infant complications. Obstet Gynecol 1985; 66:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/14\">",
"      Ju H, Chadha Y, Donovan T, O'Rourke P. Fetal macrosomia and pregnancy outcomes. Aust N Z J Obstet Gynaecol 2009; 49:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/15\">",
"      Akinbi HT, Gerdes JS. Macrosomic infants of nondiabetic mothers and elevated C-peptide levels in cord blood. J Pediatr 1995; 127:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/16\">",
"      Ahlsson FS, Diderholm B, Ewald U, Gustafsson J. Lipolysis and insulin sensitivity at birth in infants who are large for gestational age. Pediatrics 2007; 120:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/17\">",
"      Groenendaal F, Elferink-Stinkens PM. Hypoglycaemia and seizures in large-for-gestational-age (LGA) full-term neonates. Acta Paediatr 2006; 95:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/18\">",
"      Schaefer-Graf UM, Rossi R, B&uuml;hrer C, et al. Rate and risk factors of hypoglycemia in large-for-gestational-age newborn infants of nondiabetic mothers. Am J Obstet Gynecol 2002; 187:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/19\">",
"      Dollberg S, Marom R, Mimouni FB, Yeruchimovich M. Normoblasts in large for gestational age infants. Arch Dis Child Fetal Neonatal Ed 2000; 83:F148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/20\">",
"      Lackman F, Capewell V, Richardson B, et al. The risks of spontaneous preterm delivery and perinatal mortality in relation to size at birth according to fetal versus neonatal growth standards. Am J Obstet Gynecol 2001; 184:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/21\">",
"      Lapunzina P, Camelo JS, Rittler M, Castilla EE. Risks of congenital anomalies in large for gestational age infants. J Pediatr 2002; 140:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/22\">",
"      S&oslash;rensen HT, Sabroe S, Rothman KJ, et al. Relation between weight and length at birth and body mass index in young adulthood: cohort study. BMJ 1997; 315:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/23\">",
"      Seidman DS, Laor A, Gale R, et al. A longitudinal study of birth weight and being overweight in late adolescence. Am J Dis Child 1991; 145:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/24\">",
"      Chiavaroli V, Giannini C, D'Adamo E, et al. Insulin resistance and oxidative stress in children born small and large for gestational age. Pediatrics 2009; 124:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/25\">",
"      Darendeliler F, Poyrazoglu S, Sancakli O, et al. Adiponectin is an indicator of insulin resistance in non-obese prepubertal children born large for gestational age (LGA) and is affected by birth weight. Clin Endocrinol (Oxf) 2009; 70:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/26\">",
"      Giapros V, Evagelidou E, Challa A, et al. Serum adiponectin and leptin levels and insulin resistance in children born large for gestational age are affected by the degree of overweight. Clin Endocrinol (Oxf) 2007; 66:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20823/abstract/27\">",
"      Evagelidou EN, Kiortsis DN, Bairaktari ET, et al. Lipid profile, glucose homeostasis, blood pressure, and obesity-anthropometric markers in macrosomic offspring of nondiabetic mothers. Diabetes Care 2006; 29:1197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5059 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20823=[""].join("\n");
var outline_f20_21_20823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1892632\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H339470\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68825427\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68825740\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68825662\">",
"      - Genetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68825770\">",
"      - Race and ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68825693\">",
"      Maternal factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Maternal diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Maternal prepregnancy weight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Excessive maternal weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NEONATAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Birth injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1891580\">",
"      Respiratory distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Polycythemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Perinatal asphyxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1891644\">",
"      Neonatal mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1891711\">",
"      NEONATAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POTENTIAL LONG-TERM EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1892632\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5059|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/8/28805\" title=\"picture 1\">",
"      Macrosomic IDM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/35/20027\" title=\"table 1\">",
"      Syndromes fetal macrosomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/51/3899\" title=\"table 2\">",
"      Risk factors for macrosomia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=related_link\">",
"      Fetal macrosomia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=related_link\">",
"      Intrapartum management and outcome of shoulder dystocia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=related_link\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_21_20824="Influenza virus vaccine (inactivated): Pediatric drug information";
var content_f20_21_20824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Influenza virus vaccine (inactivated): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"    see \"Influenza virus vaccine (inactivated): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/53/16209?source=see_link\">",
"    see \"Influenza virus vaccine (inactivated): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14959458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Cell Culture-Derived Seasonal Influenza Vaccine (Flucelvax&reg;)",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Flucelvax&reg; (trivalent influenza virus vaccine) has been approved by the Food and Drug Administration (FDA) to provide active immunity to influenza virus. Flucelvax&reg; is the only inactivated influenza vaccine manufactured using cell culture technology and provides an alternative to influenza vaccines cultured with chicken egg protein. Availability is currently limited, but full distribution is expected during the 2012-2013 influenza season.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, refer to",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Distribution of Agriflu&trade; and Fluad&trade; in Canada: Update",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       After completing its safety information review, Health Canada has announced it is releasing two seasonal flu vaccines (Agriflu&trade; and Fluad&trade;) for immediate use in Canada. Recently, Health Canada announced that Novartis Canada had agreed to voluntarily suspend distribution of two seasonal flu vaccines (Agriflu&trade; and Fluad&trade;) in Canada. Several European countries recently suspended use of the vaccines pending examination of white floating material found clumping in the vaccines. This type of clumping has been noted previously in vaccines and has not resulted in decreased safety or effectiveness; Canadian healthcare professionals possessing the vaccines may start using them now. No reports of serious or unexpected adverse events related to the vaccines have been reported in Canada.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For further information, refer to the following website: file://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_164-eng.php",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Influenza Virus Vaccine",
"     </span>",
"     <span class=\"collapsible-date\">",
"      2012-2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The 2012-2013 influenza virus vaccine contains the same H1N1 virus as in the 2011-2012 vaccine, but different H3N2 and B viruses. The vaccine strains approved for this season in the United States are as follows: A/California/7/2009 (H1N1)-like virus, A/Victoria/361/2011 (H3N2)-like virus, and B/Wisconsin/1/2010-like virus. Because immunity to influenza virus declines over time, and because two of the three strains of the virus are different this year than last, persons should be vaccinated every year even if vaccinated during the previous season.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In addition, a variant influenza A virus (H3N2v) is currently circulating in pigs and infecting humans. Immunization with the 2012-2013 seasonal influenza vaccine is not expected to provide protection against this virus.  Symptoms of H3N2v are generally similar to those of seasonal influenza infections.  Unfortunately, standard tests used to detect influenza virus cannot differentiate between H3N2v virus from seasonal influenza A (H3N2) virus and there is a potential for false negatives with antigen detection tests. Clinicians who suspect probable H3N2v virus should contact their local or state health department for additional testing for H3N2v at a state public health laboratory. A link to recent swine exposure (within 1 week) of symptom onset should be considered a probable H3N2v case. Antiviral treatment of H3N2v influenza is the same as seasonal influenza.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       FDA approves vaccines for the 2012-2013 influenza season:",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       CDC, Interim Information about Human Infections with H3N2v Virus:",
"       <a href=\"file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm\" target=\"_blank\">",
"        file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9560252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Afluria&reg;;",
"     </li>",
"     <li>",
"      Fluarix&reg;;",
"     </li>",
"     <li>",
"      Flucelvax&reg;;",
"     </li>",
"     <li>",
"      FluLaval&reg;;",
"     </li>",
"     <li>",
"      Fluvirin&reg;;",
"     </li>",
"     <li>",
"      Fluzone&reg;;",
"     </li>",
"     <li>",
"      Fluzone&reg; High-Dose;",
"     </li>",
"     <li>",
"      Fluzone&reg; Intradermal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9560327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Agriflu&trade;;",
"     </li>",
"     <li>",
"      Fluad&trade;;",
"     </li>",
"     <li>",
"      Fluviral&reg;;",
"     </li>",
"     <li>",
"      Influvac&reg;;",
"     </li>",
"     <li>",
"      Intanza&reg;;",
"     </li>",
"     <li>",
"      Vaxigrip&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Inactivated Virus",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"      see \"Influenza virus vaccine (inactivated): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community; however, vaccination should continue throughout the influenza season as long as vaccine is available. Unless noted, the ACIP does not have a preference for any given TIV formulation when used within their specified age indications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     CDC recommendations: Infants &ge;6 months and children &lt;9 years who received a total of &ge;2 doses of seasonal influenza vaccine since July 1, 2010 need only 1 dose of the 2012-2013 seasonal influenza vaccine. If a child did not receive a total of &ge;2 doses of seasonal vaccine since July 1, 2010, if they have never received seasonal influenza vaccine (eg, this is their first season of vaccination), or if their vaccination status cannot be determined, they should receive 2 doses separated by &ge;4 weeks, in order to achieve satisfactory antibody response. Additional dosing considerations are provided when vaccination history is available prior to the 2010-2011 season; see current guidelines for additional information (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Dose frequency is per flu season.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Fluzone&reg;: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children 6-35 months: 0.25 mL/dose; 1 or 2 doses, dependent upon vaccination history",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-8 years: 0.5 mL/dose: 1 or 2 doses, dependent upon vaccination history",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;9 years and Adults: 0.5 mL/dose (1 dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fluarix&reg;: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-8 years: 0.5 mL/dose: 1 or 2 doses, dependent upon vaccination history",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;9 years and Adults: 0.5 mL/dose (1 dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fluvirin&reg;: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-8 years: 0.5 mL/dose: 1 or 2 doses, dependent upon vaccination history",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;9 years and Adults: 0.5 mL/dose (1 dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Afluria&reg;: I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Although approved for use in children &ge;5 years of age, the ACIP does not recommend use of Afluria&reg; in infants or children &lt;9 years of age due to an increased incidence of fever and febrile seizures noted during the 2010-2011 influenza season. However, if other age appropriate vaccines are not available, children 5-8 years of age who are also considered at risk for influenza complications may be given Afluria&reg; after benefits and risks are discussed with parents or caregivers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-8 years: 0.5 mL/dose;  1 or 2 doses, dependent upon vaccination history",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;9 years and Adults: 0.5 mL/dose (1 dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flucelvax&reg;, FluLaval&reg;: I.M.: Adults &ge;18 years: 0.5 mL/dose (1 dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fluzone&reg; High-Dose: I.M.: Adults &ge;65 years: 0.5 mL/dose (1 dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fluzone&reg; Intradermal: Intradermal: Adults 18-64 years: 0.1 mL/dose (1 dose)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Afluria&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, neomycin (may have trace amounts), polymyxin B (may have trace amounts), thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FluLaval&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluvirin&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, neomycin (may have trace amounts), polymyxin B (may have trace amounts), thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluzone&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Afluria&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), polymyxin B (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluarix&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, gentamicin  (may have trace amounts), hydrocortisone  (may have trace amounts), may contain natural rubber/natural latex in prefilled syringe, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flucelvax&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains polysorbate 80, may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluvirin&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, may contain natural rubber/natural latex in prefilled syringe, neomycin (may have trace amounts), polymyxin B (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluzone&reg;: Hemagglutinin 22.5 mcg/0.25 mL (0.25 mL); Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluzone&reg; High-Dose: Hemagglutinin 180 mcg/0.5 mL (0.5 mL) [contains chicken egg protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluzone&reg; Intradermal: Hemagglutinin 27 mcg/0.1 mL (0.1 mL) [contains chicken egg protein]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9560328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15840740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Fluarix&reg; Quadrivalent:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fluarix&reg; Quadrivalent: FDA approved December 2012; availability expected during the 2013-2014 influenza season.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fluarix&reg; Quadrivalent is an inactivated influenza virus vaccine approved for patients &ge;3 years of age. Seasonal quadrivalent influenza  vaccines contain two subtype A strains and two subtype B strains; trivalent influenza vaccines contain two subtype A strains and one subtype B strain.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration; the vaccine manufacturer; lot number of vaccine; the administering person's name, title, and address; and documentation of the vaccine information statement (VIS; date on VIS and date given to patient) be entered into the patient's permanent medical record.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intradermal: Fluzone&reg; Intradermal: For intradermal administration over the deltoid muscle only. Shake gently prior to use. Hold system using the thumb and middle finger (do not place fingers on windows). Insert needle perpendicular to the skin; inject using index finger to push on plunger. Do not aspirate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intramuscular: Afluria&reg;, Fluarix&reg;, FluLaval&reg;, Flucelvax&reg;, Fluvirin&reg;, Fluzone&reg;, Fluzone&reg; High-Dose: For I.M. administration only. Shake suspension well prior to use. Jet injectors should",
"     <b>",
"      not",
"     </b>",
"     be used to administer inactivated influenza vaccines unless otherwise indicated in product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: I.M. injection in the anterolateral aspect of the thigh; do not inject into the gluteal region or areas where there may be a major nerve trunk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: I.M. injection in the deltoid muscle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients at risk of bleeding (eg, patient receiving antihemophilic factor): Schedule vaccination shortly after factor is administered. Use a fine needle (23 gauge or smaller) for vaccination and apply firm pressure to the site (without rubbing) for at least 2 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If a pediatric vaccine (0.25 mL) is inadvertently administered to an adult an additional 0.25 mL should be administered to provide the full adult dose (0.5 mL). If the error is discovered after the patient has left, an adult dose should be given as soon as the patient can return. If an adult vaccine (0.5 mL) is inadvertently given to a child, no action needs to be taken.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store all products between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Potency is destroyed by freezing; do not use if product has been frozen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluarix&reg;, Flucelvax&reg;: Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Afluria&reg;, FluLaval&reg;: Discard 28 days after initial entry. Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Afluria&reg;, Fluvirin&reg;, Fluzone&reg;,  Fluzone&reg; High-Dose: Between uses, the multiple dose vial should be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunity to influenza A and B virus strains contained in the vaccine",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Trade Name",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Manufacturer",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approval age",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          *Note:",
"         </b>",
"         Due to an increased incidence of fever and febrile seizures in infants and children &lt;5 years of age observed with the use of the 2010 Southern Hemisphere formulation of Afluria&reg;, the Advisory Committee on Immunization Practices (ACIP) recommends that Afluria&reg; should not be used in infants and children 6 months through 8 years of age, although use in 5-8 years of age is reserved for patients if no other age-appropriate vaccine is available.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Fluzone&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Sanofi Pasteur",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;6 months",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Fluarix&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         GlaxoSmithKline",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;3 years",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Fluvirin&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Novartis vaccine",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;4 years",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Afluria&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         CSL Biotherapies",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;5 years*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Flucelvax&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Novartis vaccine",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;18 years",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         FluLaval&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         ID Biomedical Corporation of Quebec",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;18 years",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Fluzone&reg; Intradermal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Sanofi Pasteur",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18-64 years",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Fluzone&reg; High-Dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Sanofi Pasteur",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;65 years",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Recommendations for annual",
"      <span style=\"text-decoration: underline\">",
"       seasonal",
"      </span>",
"      influenza vaccination:",
"     </b>",
"     The Advisory Committee on Immunization Practices (ACIP) recommends annual vaccination with the seasonal trivalent inactivated influenza vaccine (TIV) (injection) for all persons &ge;6 months of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     When vaccine supply is limited, target groups for vaccination (those at higher risk of complications from influenza infection and their close contacts) include the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; All infants &ge;6 months and children 12-59 months of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Persons &ge;50 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Residents of nursing homes and other chronic-care facilities that house persons of any age with chronic medical conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Adults and children with chronic disorders of the pulmonary or cardiovascular systems, including children with asthma, bronchopulmonary dysplasia, cystic fibrosis, and congenital heart disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Adults and children who have required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, sickle cell disease, human immunodeficiency virus (HIV) infection, or immunosuppression (including immunosuppression caused by medications)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Infants, children, and adolescents (6 months to 18 years of age) who are receiving long-term aspirin therapy and therefore, may be at risk for developing Reye's syndrome after influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Women who are or will be pregnant during influenza season",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Adults and children with cognitive or neurologic/neuromuscular conditions including conditions such as spinal cord injuries or seizure disorders which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Persons who live with or care for persons at high risk for influenza-related complications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Healthy household contacts and caregivers of neonates, infants, and children aged 0-59 months and persons at high risk for severe complications from influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Healthcare workers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; American Indians/Alaska Natives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Morbidly obese (BMI &ge;40)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9560326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fluarix&reg; may be confused with Flarex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Influenza virus vaccine may be confused with flumazenil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Influenza virus vaccine may be confused with tetanus toxoid and tuberculin products. Medication errors have occurred when tuberculin skin tests (PPD) have been inadvertently administered instead of tetanus toxoid products and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluarix [U.S., Canada, and multiple international markets] may be confused with Flarex brand name for fluorometholone [U.S. and multiple international markets] and Fluorex brand name for fluoride [France]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9560260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adverse reactions in adults &ge;65 years of age may be greater using the high-dose vaccine, but are typically mild and transient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest tightness, facial edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, drowsiness, fatigue, fever, headache, irritability, malaise, migraine, shivering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased, diarrhea, nausea, sore throat, upper abdominal pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (including bruising, erythema, induration, inflammation, pain, soreness [&le;64%; may last up to 2 days], pruritus, swelling, tenderness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia (may start within 6-12 hours and last 1-2 days; incidence generally equal to placebo in adults; occurs more frequently than placebo in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Red eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, nasal congestion, nasopharyngitis, pharyngolaryngeal pain, rhinitis, upper respiratory tract infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, anaphylaxis, angioedema, convulsions, erythema multiforme, facial palsy (Bell&rsquo;s palsy), Guillain-Barr&eacute; syndrome (GBS), Henoch-Sch&ouml;nlein purpura, hypersensitivity reaction, limb paralysis, lymphadenopathy, myelitis (including encephalomyelitis and transverse myelitis), neuralgia, oculorespiratory syndrome (ORS; acute, self-limited reaction with ocular and respiratory symptoms), optic neuritis/neuropathy, paralysis, photophobia, serum sickness, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, urticaria, vasculitis, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to influenza virus vaccine or any component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional contraindications for Afluria&reg;, Fluarix&reg;, FluLaval&reg;, Fluvirin&reg;, Fluzone&reg;, Fluzone&reg; High-Dose, Fluzone&reg; Intradermal: Manufacuter labeling: Allergy to eggs or egg products, chicken, chicken feathers, or chicken dander",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo-/radiation therapy or other immunosuppressive therapy including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Antigenic response may not be as great as expected in HIV-infected persons with CD4 cells &lt;100/mm",
"     <sup>",
"      3",
"     </sup>",
"     and viral copies of HIV type 1 &gt;30,000/mL. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with history of febrile convulsions. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009). Use with caution in patients with a history of Guillain-Barr&eacute; syndrome (GBS) which occurred within 6 weeks of receiving a prior influenza vaccine dose; the benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at high risk for complications of influenza. Use caution in patients with thrombocytopenia, any coagulation disorder, or receiving anticoagulants.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Most products are manufactured with chicken egg protein (expressed as ovalbumin content). The ovalbumin content may vary from season to season and lot to lot of vaccine. Allergy to eggs must be distinguished from allergy to the vaccine. Recommendations are available from the CDC regarding influenza vaccination to persons who report egg allergies; however, a prior severe allergic reaction to influenza vaccine, regardless of the component suspected, is a contraindication to vaccination (CDC, 2012). Flucelvax&reg; is an inactivated influenza vaccine manufactured using cell culture technology and provides an alternative to vaccines cultured with chicken egg protein.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe allergic reactions including anaphylaxis may occur; immediate treatment for anaphylactic/anaphylactoid reaction should be available. Inactivated influenza virus vaccine may be preferred over live virus vaccine for household members, healthcare workers, and others coming in close contact with severely immunosuppressed persons requiring care in a protected environment. Influenza vaccines from previous seasons must not be used. An increased number of febrile seizures has been reported in children, especially those 12-23 months of age, who concomitantly received inactivated influenza vaccine and pneumococcal conjugate vaccine (13-Valent); no change  in vaccination schedule is recommended by the ACIP (AAP, 2011; CDC, 2012). An increased incidence of fever and febrile seizures in children &lt;5 years of age has been observed with the use of the 2010 Southern Hemisphere formulation of Afluria&reg;; febrile events have also been reported in children 5 to &lt;9 years of age. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products may contain polysorbate 80 (Tween&reg; 80) which may cause allergic reactions in susceptible individuals. Products may contain gentamicin, kanamycin, neomycin, polymyxin, or thimerosal; packaging may contain natural latex rubber; use caution in patients with known sensitivity to these agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pneumococcal Conjugate Vaccine (13-Valent): May diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). Influenza Virus Vaccine (Inactivated) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Management: Immune response to these vaccines may be diminished when given concomitantly to patients 65 years old or older.  When practical, consider separating doses of these vaccines by 1 month or more for these patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer specific) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with all products. When conducted, adverse events were not observed in animal studies. Inactivated influenza vaccine has not been shown to cause fetal harm and has been shown to be safe and effective when given to pregnant women. Following maternal immunization with the influenza virus vaccine, vaccine specific antibodies are observed in the newborn.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pregnant women are at an increased risk of complications from influenza infection (Rasmussen, 2008). Influenza vaccination with the inactivated influenza vaccine (IIV) is recommended for all women who are or will become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine. Pregnant women should observe the same precautions as nonpregnant women to reduce the risk of exposure to influenza and other respiratory infections. When vaccine supply is limited, focus on delivering the vaccine should be given to women who are pregnant or will be pregnant during the flu season, as well as mothers of newborns and contacts or caregivers of children &lt;5 years of age (CDC, 2010). Most available studies show a decrease in influenza-related illnesses in pregnant women as well as children &lt;6 months of age following maternal vaccination during pregnancy, thereby supporting current recommendations that all pregnant women should be vaccinated (Zaman, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to the influenza vaccine during pregnancy to the",
"     <i>",
"      Vaccines and Medications in Pregnancy Surveillance System",
"     </i>",
"     (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972. Women exposed to Flulaval&reg; or Fluarix&reg; during pregnancy may also contact the GlaxoSmithKline registry at 888-452-9622. Healthcare providers may enroll women exposed to Fluzone&reg; Intradermal during pregnancy in the Sanofi Pasteur vaccination registry at 800-822-2463.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13222718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to re-establish adequate cerebral perfusion. For those individuals who report a history of egg allergy but it is determined that the inactivated vaccine can be used, observe vaccine recipient for at least 30 minutes after receipt of vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes immunity to influenza virus by inducing specific antibody production",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1047920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Protective antibody levels achieved ~3 weeks after vaccination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Protective antibody levels persist approximately &ge;6 months",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/53/16209?source=see_link\">",
"      see \"Influenza virus vaccine (inactivated): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if you experience a high fever, seizures, or allergic reaction (difficulty breathing, hives, weakness, dizziness, fast heart beat). Inactivated influenza virus vaccine is safe to administer to mothers who are breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pharmacies will stock the formulations(s) standardized according to the USPHS requirements for the season. Influenza vaccines from previous seasons must not be used. It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community; however, vaccination should continue throughout the influenza season as long as vaccine is available. Influenza is highly contagious. Incubation period is 1-3 days. Patients are most contagious during the 24 hours before the onset of symptoms and during their most symptomatic period.",
"     <b>",
"      Note:",
"     </b>",
"     Some states have restrictions that prohibit the use of vaccines containing greater than trace amounts of thimerosal in pregnant women or children &lt;3 years of age (check individual state statutes).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20824/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, \"Policy Statement-Recommendations for Prevention and Control of Influenza in Children, 2011-2012,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , September 2, 2011.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20824/abstract-text/21890834/pubmed\" id=\"21890834\" target=\"_blank\">",
"        21890834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20824/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Note to Providers: Febrile Seizures Associated With TIV &amp; PCV13.\" Available at file://www.cdc.gov/vaccines/pubs/vis/tiv-pcv-note.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-8):1-62. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20824/abstract-text/20689501/pubmed\" id=\"20689501\" target=\"_blank\">",
"        20689501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) &minus; United States, 2012-13 Influenza Season,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61:613-8. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20824/abstract-text/22895385/pubmed\" id=\"22895385\" target=\"_blank\">",
"        22895385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20824/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update on Febrile Seizures in Children Following Vaccination With Influenza Vaccines and Pneumococcal Vaccines.\" Last updated October 2011. Available at",
"      <a href=\"file://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html\" target=\"_blank\">",
"       file://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20824/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/21/20824/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, \"FDA Updated Communication on Use of Jet Injectors With Inactivated Influenza Vaccines.\" Last updated October 2011. Available at",
"      <a href=\"file://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm\" target=\"_blank\">",
"       file://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12940 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20824=[""].join("\n");
var outline_f20_21_20824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959458\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560252\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560327\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047915\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047908\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600938\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560328\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840740\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047918\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047911\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047917\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560326\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560260\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047921\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047907\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047906\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299519\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221011\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600925\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600926\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13222718\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047905\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047920\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047913\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047922\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12940|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=related_link\">",
"      Influenza virus vaccine (inactivated): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/53/16209?source=related_link\">",
"      Influenza virus vaccine (inactivated): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_21_20825="MPGN Light II";
var content_f20_21_20825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Membranoproliferative glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of membranoproliferative glomerulonephritis (MPGN) showing thickening of all capillary walls with double contours (long arrows) and focal areas of cellular proliferation (short arrow). The double-contour or tram-track appearance represents interposition of mesangial cell elements with new glomerular basement membrane synthesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20825=[""].join("\n");
var outline_f20_21_20825=null;
var title_f20_21_20826="Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis";
var content_f20_21_20826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/21/20826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20826/contributors\">",
"     John Bernardo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/21/20826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20826/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/21/20826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/21/20826/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/21/20826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miliary tuberculosis (TB) refers to clinical disease resulting from the hematogenous dissemination of Mycobacterium tuberculosis. The term miliary was coined in 1700 by John Jacobus Manget, who likened the appearance of the involved lung, with its surface covered with firm small white nodules, to millet seeds (",
"    <a class=\"graphic graphic_picture graphicRef76174 \" href=\"UTD.htm?7/6/7269\">",
"     picture 1",
"    </a>",
"    ). Originally a pathologic and then a radiographic description, the term miliary TB is now used to denote all forms of progressive, widely disseminated hematogenous TB. Miliary TB can arise as a result of progressive primary infection or via reactivation of a latent focus with subsequent spread.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, treatment, and prevention of miliary TB will be reviewed here. The pathogenesis and epidemiology of miliary TB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34150?source=see_link\">",
"     \"Epidemiology and pathology of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large retrospective series provide much of the data on the clinical features of miliary tuberculosis (TB) (",
"    <a class=\"graphic graphic_table graphicRef77719 \" href=\"UTD.htm?36/31/37372\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. While these studies include a relatively large number of patients, they differ markedly by year, inclusion criteria, country, and type of medical center, so direct comparison is difficult.",
"   </p>",
"   <p>",
"    The clinical presentation of miliary TB is highly variable; manifestations can be acute but are more likely to be subacute or chronic. In highly endemic areas miliary TB may be associated with reinfection. Development of miliary TB during primary infection can present with relatively acute onset and rapid clinical course. Acute disease may be fulminant, including multiorgan system failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/7\">",
"     7",
"    </a>",
"    ], a syndrome of septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/8\">",
"     8",
"    </a>",
"    ], and acute respiratory distress syndrome (ARDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subacute or chronic presentations of miliary TB are more common than acute disease. These patients may present with failure to thrive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/5\">",
"     5",
"    </a>",
"    ], fever of unknown origin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/2\">",
"     2",
"    </a>",
"    ], or dysfunction of one or more organ systems [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/11\">",
"     11",
"    </a>",
"    ]. The most common extrapulmonary sites of disease include the lymphatic system, bones and joints, and the liver. Night sweats are frequent. Rigors are unusual but have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one series including 38 patients, the median duration of illness was two months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/2\">",
"     2",
"    </a>",
"    ]. Symptoms and signs of miliary TB are described in the Tables (",
"    <a class=\"graphic graphic_table graphicRef60000 \" href=\"UTD.htm?28/61/29660\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63136 \" href=\"UTD.htm?24/27/25020\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis of miliary TB is often missed due to the non-specific nature of the presentation. In one review, approximately 20 percent of miliary TB cases in the United States were diagnosed postmortem [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/14\">",
"     14",
"    </a>",
"    ]. Among HIV-infected patients in Africa, previously unrecognized disseminated tuberculosis has been identified at autopsy in as many as 40 percent of hospital deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary disease is noted in over 50 percent of patients with miliary TB in most series. Patients reported dyspnea or cough and had rales or rhonchi on physical examination. Hypoxemia was common. Pleuritic chest pain with accompanying pleural rub or other signs of a pleural effusion have also been well described.",
"   </p>",
"   <p>",
"    As noted above, miliary TB is a rare cause of acute respiratory failure and ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/9,10,16-18\">",
"     9,10,16-18",
"    </a>",
"    ]. In one series from a region endemic for TB in South Africa, it was estimated that 2 percent of cases of ARDS were associated with disseminated TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/19\">",
"     19",
"    </a>",
"    ]. Another study suggested that the diagnosis of TB is more likely to be delayed or missed entirely in patients presenting with acute respiratory failure as opposed to more typical symptoms of pulmonary or pleural TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7880259\">",
"    <span class=\"h2\">",
"     Lymphatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lymphatic TB usually present with signs and symptoms referable to the site of disease, although constitutional symptoms may be the sole complaint. Cervical lymph node enlargement, with or without other symptoms, is a frequent presentation of cervical tuberculous adenitis.",
"   </p>",
"   <p>",
"    Within the chest, hilar (usually unilateral) and mediastinal lymph node enlargement may reflect either primary TB or reactivation disease. Enlarged intrathoracic nodes may cause extrinsic airway compression leading to focal wheezing or airway obstruction, especially in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27768?source=see_link\">",
"     \"Tuberculous lymphadenitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7880317\">",
"    <span class=\"h2\">",
"     Bone and joint disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, bone or joint TB should be suspected in individuals at risk for TB who present with bone or joint pain (including back pain) with or without focal swelling or fever [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,6,21\">",
"     1,6,21",
"    </a>",
"    ]. The course usually is indolent and pain usually is the first presenting symptom. Spinal TB (Pott&rsquo;s disease) may present in children as scoliosis or a limp [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/22\">",
"     22",
"    </a>",
"    ]. The diagnosis often is delayed and may be difficult to establish. Radiographic findings can be nonspecific; early features may include soft tissue swelling (especially of the anterior portions of the vertebral body) with bone demineralization and preservation of joint surfaces. With chronic disease, complete destruction of bone with local sclerosis may be seen, accompanied by loss of structural support and spinal deformity. Disease is most common in the lower thoracic and lumbar vertebrae. Extension of the infectious process to surrounding soft tissue may create cold abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/23\">",
"     23",
"    </a>",
"    ]. Involvement of multiple vertebrae is characteristic of Pott&rsquo;s disease. Computed tomography (CT) and magnetic resonance imaging (MRI) can identify early lesions not seen on plain radiographs. Confirmation of a diagnosis of TB requires aspiration or biopsy and culture of the affected tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forms of gastrointestinal involvement include hepatic disease, tuberculous enteritis, and tuberculous peritonitis. Miliary TB may also present as pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/24\">",
"     24",
"    </a>",
"    ] or cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The liver is frequently involved in disseminated TB. Signs and symptoms include diffuse abdominal pain or pain localizing to the right upper quadrant, nausea, vomiting and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/26\">",
"     26",
"    </a>",
"    ]. Histopathologic sections of involved liver demonstrate scattered granulomatous lesions that on gross examination have the appearance of millet seeds (",
"    <a class=\"graphic graphic_picture graphicRef83409 \" href=\"UTD.htm?14/18/14631\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/27\">",
"     27",
"    </a>",
"    ]. Liver function test abnormalities are common, including elevated alkaline phosphatase and transaminases in 83 and 42 percent of patients, respectively, in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1\">",
"     1",
"    </a>",
"    ]. Cholestatic jaundice is also well-documented in miliary TB. Rarely fulminant hepatic failure can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/28\">",
"     28",
"    </a>",
"    ]. The diagnosis is established by identifying the organism obtained from a biopsy sample in culture.",
"   </p>",
"   <p>",
"    Tuberculous enteritis consists of relatively vague, nonspecific symptoms and signs. A presumptive diagnosis can be made in the presence of known active pulmonary TB. However, chest imaging is typically positive (for active or healed TB) in less than half of cases. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43862?source=see_link\">",
"     \"Tuberculous enteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tuberculous peritonitis usually develops following spread of infection from adjacent organs. It should be suspected in patients at risk for TB who present with ascites. Symptoms of fever, fatigue, and abdominal pain are common. Ascites fluid usually demonstrates lymphocytosis, elevated protein, and elevated inflammatory markers. Culture of ascites fluid or of peritoneal tissue is required to confirm the diagnosis. The surface of the peritoneum may demonstrate miliary lesions on visual examination; biopsy of these lesions demonstrates caseating granulomas, with or without acid-fast staining organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36614?source=see_link\">",
"     \"Tuberculous peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Central nervous system disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) disease, such as meningitis or tuberculoma, was observed in 15 to 20 percent of patients with TB in two large series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Among patients with tuberculous meningitis, about one-third to one-half had miliary TB; in one series meningeal involvement was evident postmortem in 54 percent of cases of miliary TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high index of suspicion is necessary to make a timely diagnosis, since presenting symptoms and findings on examination often are nonspecific. In adults, CNS TB typically presents indolently, with headache, low-grade fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal neurological findings. In children or immunocompromised hosts, the disease may present as acute meningitis.",
"   </p>",
"   <p>",
"    CT with contrast or MRI with gadolinium of the brain may demonstrate hydrocephalus, parenchymal lesions, or leptomeningeal and basal cistern enhancement. Cerebrospinal fluid (CSF) pressure usually is elevated; the fluid usually demonstrates high protein, very low glucose, and lymphocytosis, although polymorphonuclear leukocytes may be seen early in the disease. Isolation of M. tuberculosis by culture confirms the diagnosis (although sensitivity is 50 to 60 percent), and nucleic amplification testing of the CSF may support the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Nucleic acid amplification by polymerase chain reaction (PCR) for MTb DNA in the CSF is not approved by the United States Food and Drug Administration (FDA), although many laboratories offer internally validated PCR testing. However, treatment should be initiated as soon as TB is suspected in order to minimize the risk of long term neurologic sequelae or death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link\">",
"     \"Central nervous system tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genitourinary and adrenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB of the urinary tract may present with hematuria, proteinuria, and \"sterile\" pyuria. In the kidney the disease frequently localizes to the renal papillae, and characteristic distortion of the collecting system tract may be seen radiographically. Flank pain, hydronephrosis, and cystitis indicate more severe disease, and spread to the genitalia may occur. Diagnosis is established by culture of the organism from the urine; acid-fast microscopy generally is not performed on urine samples because of the normal presence of nonpathogenic, nontuberculous mycobacteria in many individuals. Focal scarring of the kidneys and the collecting system may occur even after successful treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14005?source=see_link\">",
"     \"Renal disease in tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TB of the female genital tract may occur in the setting of primary or reactivation disease. Menstrual abnormalities in the setting of known TB infection should prompt consideration of female genital tract involvement. Ultrasonography or other radiographic studies may be helpful in localizing lesions. The diagnosis is established with open biopsy, dilation and curettage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colposcopy, with histologic examination and culture of biopsy materials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scrotal pain, swelling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epididymal or prostate tenderness in the setting of known TB infection should prompt consideration of male genital tract involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/35\">",
"     35",
"    </a>",
"    ]. Urine culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy of affected tissue for culture are necessary for diagnosis.",
"   </p>",
"   <p>",
"    Adrenal insufficiency has been associated with miliary TB and involvement of the adrenals may be found in as many as 42 percent of autopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/4,36\">",
"     4,36",
"    </a>",
"    ]. Overt adrenal insufficiency is less common, occurring in 1 percent of reported cases of miliary TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,36\">",
"     1,36",
"    </a>",
"    ]. In a prospective study including 30 patients with miliary TB, adrenal function was abnormal in 1 of 30 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/37\">",
"     37",
"    </a>",
"    ]. Among 55 patients with TB involvement of the adrenal gland in one series, 12 percent presented with clinical manifestations of Addison's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8444360\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is unusual in miliary TB. Autopsy series report an incidence of less than 10 percent, almost always clinically silent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/29,38\">",
"     29,38",
"    </a>",
"    ]. The most common single form of cardiovascular TB is pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Myocardial disease is much less frequent; one patient with sudden cardiac death due to myocardial dissemination has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/39\">",
"     39",
"    </a>",
"    ]. Tuberculous endocarditis is also very rare [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tuberculous pericarditis generally is a late diagnosis. The chest radiograph usually demonstrates an enlarged cardiac silhouette, and echocardiography may show signs of constriction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/41\">",
"     41",
"    </a>",
"    ]. A positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    is observed in more than 85 percent of patients, although this number is lower in the immunocompromised [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. Pericardial fluid and biopsy can be obtained for mycobacterial smear and culture, but the yield from these specimens is not as high as for pleural fluid or tissue. Thus, presumptive therapy often is administered to patients with evidence of constrictive pericardial disease and a positive tuberculin skin test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"     \"Tuberculous pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disseminated TB can be associated with mycotic aneurysms of the ascending or descending aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/46\">",
"     46",
"    </a>",
"    ]. Potential mechanisms include spread from a lymph node or from vertebral osteomyelitis to the aorta, followed by hematogenous dissemination. Embolization to the aortic wall vasa vasorum during hematogenous spread from another focus can also occur. Aneurysm rupture after the initiation of antituberculous chemotherapy has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7880479\">",
"    <span class=\"h2\">",
"     Cutaneous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous disease is rare in miliary TB. The most common presentation is TB cutis miliaris disseminata, which consists of 5 to 10 mm macules and papules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/47\">",
"     47",
"    </a>",
"    ]. A generalized rash which resembles a lichenoid tuberculid response has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/13\">",
"     13",
"    </a>",
"    ]. Advanced HIV may also predispose to skin manifestations of disseminated TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=see_link\">",
"     \"Cutaneous manifestations of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy series of miliary TB describe seeding of every organ in the body [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/29\">",
"     29",
"    </a>",
"    ]. Laryngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/49\">",
"     49",
"    </a>",
"    ] and otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/50\">",
"     50",
"    </a>",
"    ] have been reported as clinical presentations of miliary TB. Involvement of the thyroid gland with clinical hyperthyroidism or hypothyroidism has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One large autopsy series which included eye examinations found tubercles in 50 percent of eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/29\">",
"     29",
"    </a>",
"    ], suggesting that a good dilated examination might be helpful in the diagnosis of hematogenous spread of TB. Choroidal tubercles are said to be specific for miliary TB, although they were rarely found in the large clinical series where dilated examinations were not routinely performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5767?source=see_link\">",
"     \"Tuberculosis and the eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many laboratory abnormalities may be observed in miliary TB (",
"    <a class=\"graphic graphic_table graphicRef76492 \" href=\"UTD.htm?31/63/32764\">",
"     table 4",
"    </a>",
"    ). Hematologic abnormalities are prominent. Normocytic, normochromic anemia is seen in approximately one-half of the patients in most series. Most patients have a normal white blood cell count, but leukopenia and leukocytosis occur in a minority of patients with roughly equal frequency. Miliary TB should be considered in the differential diagnosis of patients with a leukocytosis or left shift when initial evaluation does not reveal a typical bacterial etiology, especially when accompanied by anemia. Leukemoid reactions are also described and have even led to a misdiagnosis of leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Monocytosis occurs but is less common. Thrombocytopenia and thrombocytosis are also reported.",
"   </p>",
"   <p>",
"    Pancytopenia is another hematologic manifestation, which should raise concern for miliary TB; this may be due to marrow infiltration alone or may be a manifestation of an underlying hematologic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/54\">",
"     54",
"    </a>",
"    ]. Cases of the histiocytic hemophagocytic syndrome associated with miliary TB have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/55\">",
"     55",
"    </a>",
"    ]. Some cases have resolved with antituberculous chemotherapy alone, although associated conditions, such as viral infections, were not always excluded and response to steroids may have been non-specific.",
"   </p>",
"   <p>",
"    Overt disseminated intravascular coagulation is rare; it has been described in acute, fulminant disease. Milder coagulation abnormalities have been described more frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1\">",
"     1",
"    </a>",
"    ]. The erythrocyte sedimentation rate and other acute phase reactants are elevated in the majority of patients with miliary TB. Polyclonal gammaglobulinemia is also common [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyponatremia is the most common electrolyte abnormality observed in miliary TB. It is presumed to be due to the same problems with regulation of antidiuretic hormone seen in other pulmonary processes, since not all series note a correlation with central nervous system (CNS) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/2\">",
"     2",
"    </a>",
"    ]. Hypercalcemia is rare but may be seen in miliary TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sterile pyuria was found in 32 percent of patients with miliary TB in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/2\">",
"     2",
"    </a>",
"    ], without positive mycobacterial cultures from the urinary tract. Urine cultures may also be positive for M. tuberculosis in miliary TB, in the absence of an abnormal urine sediment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two series of cases of miliary tuberculosis (TB) provide the best overview of pulmonary findings, since a miliary pattern on chest radiograph was not required for study inclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. More than two-thirds of patients with the diagnosis of disseminated TB had a chest radiograph with a miliary pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic appearance is a faint, reticulonodular infiltrate distributed fairly uniformly throughout the lungs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63302 \" href=\"UTD.htm?30/61/31698\">",
"     image 1",
"    </a>",
"    ). This miliary pattern may only become apparent days or weeks after presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,3,6\">",
"     1,3,6",
"    </a>",
"    ]. This finding is thought to reflect nodular interstitial spread without significant alveolar involvement, although it has been demonstrated that by the time the miliary nodules are large enough to be appreciated on a plain chest radiograph, they typically involve the adjacent alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, pathologic conditions that initially involve alveoli, such as alveolar hemorrhage, pulmonary edema or inhalational diseases, can appear as early small nodules. These so-called \"acinar nodules\" are described as larger (5 to 10 mm) and more heterogeneous than classic miliary TB, but overlap occurs, making the appearance of many of these conditions indistinguishable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/58\">",
"     58",
"    </a>",
"    ]. The differential diagnosis of a miliary chest radiography pattern is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef70568 \" href=\"UTD.htm?29/20/30028\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other chest radiograph abnormalities include pleural reactions, hilar or mediastinal adenopathy and other evidence of active or healed parenchymal TB (interstitial or alveolar infiltrates or cavities). A miliary pattern can be seen in addition to non-miliary disease. Normal chest radiographs may be observed in up to one-half of patients with disseminated TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/59\">",
"     59",
"    </a>",
"    ]. In some cases abnormalities may be subtle and appreciated only after review with an experienced chest radiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution computed tomography (HRCT) of the chest is more sensitive for miliary TB than plain chest radiography and has improved antemortem diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/60\">",
"     60",
"    </a>",
"    ]. Numerous 2 to 3 mm nodules can be visualized, distributed throughout the lung (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77071 \" href=\"UTD.htm?32/49/33553\">",
"     image 2",
"    </a>",
"    ). Septal thickening usually accompanies these nodules. These findings are sensitive but not necessarily specific. In series correlating clinical and pathologic findings with HRCT, disseminated nodules were found in many other infections (Haemophilus influenzae, Mycoplasma pneumoniae, Candida albicans) and noninfectious diseases (sarcoidosis, metastatic adenocarcinoma, lymphoma, amyloidosis, hypersensitivity pneumonitis, and pneumoconiosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallium scans can show diffuse pulmonary and extrapulmonary uptake in miliary TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/63\">",
"     63",
"    </a>",
"    ]. However, sensitivity and specificity are limited; patients with miliary TB and evidence of miliary patterns on chest imaging may have negative gallium scans.",
"   </p>",
"   <p>",
"    Abdominal imaging may also show findings consistent with miliary TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/64\">",
"     64",
"    </a>",
"    ]. Contrast-enhanced abdominal computed tomography (CT) may demonstrate multiple foci of low attenuation, typically without enhancement after intravenous contrast administration. Ultrasound may reveal multiple echogenic lesions with surrounding hypoechoic halos.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing a diagnosis of miliary tuberculosis (TB) requires sufficient clinical suspicion; the diagnosis can be challenging due to nonspecific clinical and symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/65\">",
"     65",
"    </a>",
"    ]. Careful diagnostic evaluation of extrapulmonary findings is warranted whether systemic disease is suspected in the setting of known pulmonary TB, or whether extrapulmonary disease is the initial presenting factor prompting clinical attention. This is important because the nature and scope of extrapulmonary findings observed on diagnostic evaluation may influence the approach to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13124464\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evaluation begins with a thorough history and physical examination (including a dilated funduscopic examination, which can be helpful in the diagnosis of hematogenous spread of TB). In general, an evaluation for pulmonary disease is warranted in all patients in whom disseminated TB is suspected (",
"    <a class=\"graphic graphic_table graphicRef80879 \" href=\"UTD.htm?38/31/39420\">",
"     table 6",
"    </a>",
"    ), including chest radiography (followed by computed tomography if warranted), sputum for acid fast smear and culture, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    . If sputum cannot be obtained, evaluation of bronchoscopy or gastric secretions may be warranted. In addition, mycobacterial blood culture should be performed using a lysis centrifugation or automated broth system designed for mycobacterial culture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. In regions where available, molecular tests can be useful rapid diagnostic tools. (See",
"    <a class=\"local\" href=\"#H13124651\">",
"     'Tuberculin skin test'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Acid fast smear and culture'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Molecular tests'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subsequent diagnostic approach should be tailored to localizing signs or symptoms of disease involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with neurologic signs or symptoms should undergo neuroimaging and lumbar puncture (if feasible). The most common radiographic findings in tuberculous meningitis are basal meningeal enhancement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hydrocephalus. Cerebrospinal fluid (CSF) should be analyzed for cell count, protein and glucose concentrations, as well as acid fast staining and culture for bacterial and mycobacterial organisms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link\">",
"       \"Central nervous system tuberculosis\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      In the setting of pleural effusion, pericardial effusion or ascites, fluid should be obtained for evaluation of cell count, protein, glucose, and LDH concentrations, as well as acid fast staining and culture for bacterial and mycobacterial organisms. Pleural biopsy is warranted in the setting of moderate to high suspicion for TB when pleural fluid evaluation is not diagnostic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=see_link\">",
"       \"Tuberculous pleural effusions in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"       \"Tuberculous pericarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36614?source=see_link\">",
"       \"Tuberculous peritonitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with symptoms referable to the gastrointestinal or genitourinary tract should undergo radiographic imaging of the involved site(s). Gastrointestinal disease may warrant further endoscopic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical evaluation. Suspected genitourinary disease should prompt urine AFB culture (urine AFB smears are less useful since they can be confounded by other, nontuberculous mycobacteria). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14005?source=see_link\">",
"       \"Renal disease in tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with symptoms localizing to other extrapulmonary sites (lymph nodes,",
"      <span class=\"nowrap\">",
"       bones/joints,",
"      </span>",
"      skin, and other sites) should undergo evaluation as warranted depending on the involved organ system. Radiographic imaging may be warranted. Tissue biopsy may be required to establish a definitive diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27768?source=see_link\">",
"       \"Tuberculous lymphadenitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"       \"Skeletal tuberculosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=see_link\">",
"       \"Cutaneous manifestations of tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biopsy specimens from the lung, bone marrow, pericardium, lymph nodes, bones, joints, bowel, liver, brain, or other tissues allow for both histopathologic examination and culture. Liver biopsies are generally associated with the highest yield for diagnosis of extrapulmonary TB. In two series, granulomas were demonstrated more frequently in liver biopsies (91 to 100 percent) than bone marrow biopsies (31 to 82 percent) or transbronchial biopsies (72 and 63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Lymph nodes and serosal biopsies also had high yields in patients in these series. The biopsy yield is likely to be increased in the setting of associated clinical or laboratory abnormalities. Biopsy specimens should be collected with and without fixative; culture requires specimens without fixative. (See",
"    <a class=\"local\" href=\"#H13124590\">",
"     'Histopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no role for serologic testing in diagnosis of TB; such tests have very low specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. While large numbers of individuals worldwide have TB antibodies, only about 10 percent of them go on to develop active disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13124472\">",
"    <span class=\"h2\">",
"     Diagnostic tools",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13124651\">",
"    <span class=\"h3\">",
"     Tuberculin skin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    can be a supportive diagnostic tool if positive, but a negative skin test does not exclude the diagnosis; anergy is observed more frequently among patients with miliary TB than those with pulmonary or isolated extrapulmonary involvement and may be as high as 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Tuberculin skin test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Acid fast smear and culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid fast culture of tissue, fluid, or drainage from an infected locus is the standard tool for establishing the diagnosis of TB. Acid-fast microscopy may support a diagnosis of TB, especially if organisms or caseating granulomas are seen. The frequency of positive smears or cultures is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef70362 \" href=\"UTD.htm?5/18/5420\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These data make several important points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smears for acid fast bacilli were positive in a minority of patients when only a single site was sampled; the probability of a positive smear increased with the number of sites sampled. Thus when possible, samples of multiple sites (sputum, gastric aspirate, pleural fluid, ascites, urine) should be examined for the presence of acid-fast bacilli.",
"     </li>",
"     <li>",
"      Gastric aspirate cultures were frequently positive in these series. However, it was not clear how often they were positive when sputum smears were negative. It is reasonable to obtain gastric aspirates if sputum smears are not available or negative.",
"     </li>",
"     <li>",
"      Bronchoscopy may be warranted if acid-fast bacilli are not detected at multiple sites (sputum, gastric aspirate, pleural fluid, ascites, urine); in general bronchoscopy is most useful when there is evidence of pulmonary involvement on chest radiography [",
"      <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. In the setting of subacute or chronic presentation with negative sputum smears, it is reasonable to delay bronchoscopy until cultures are negative for one to two weeks, particularly if a rapid diagnostic assay is available. In the setting of acute presentation or in the absence of rapid diagnostic tools, prompt bronchoscopy is warranted. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Molecular tests'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Smears should be stained with the acid-fast fluorochrome dye, auramine-O, which is more sensitive than the conventional Ziehl-Nielsen stain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/76\">",
"     76",
"    </a>",
"    ]. Rapid probes can be applied to smear-positive sputum specimens to confirm the diagnosis of M. tuberculosis (in areas where available) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/77\">",
"     77",
"    </a>",
"    ]. Specimens should then be inoculated into a commercial automated radiometric detection system (BACTEC, Becton Dickson), which is faster and more sensitive than standard techniques using solid medium for the isolation of M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/78\">",
"     78",
"    </a>",
"    ]. M. tuberculosis can be differentiated from commonly isolated non-tuberculous mycobacteria by hybridization using nucleic acid probes on the liquid medium.",
"   </p>",
"   <p>",
"    Mycobacterial blood cultures (preferably using lysis centrifugation techniques) should be performed in all patients in whom hematogenous dissemination is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/66\">",
"     66",
"    </a>",
"    ]. Positive blood cultures in disseminated TB are relatively rare though may be observed in immunocompromised patients, including those with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/68,79\">",
"     68,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13124590\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathology of tissue biopsy specimens in the setting of TB typically demonstrates granulomatous inflammation. Granulomas of TB characteristically contain epithelioid macrophages, Langhans giant cells, and lymphocytes. The centers of tuberculous granulomas often have characteristic caseation (\"cheese-like\") necrosis; organisms may or may not be seen with acid-fast staining. The demonstration of characteristic caseating granulomas on a tissue section in the appropriate clinical and epidemiologic circumstances strongly supports a diagnosis of active TB, but it is not pathognomonic; culture is required to establish a laboratory diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Molecular tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In regions where available, molecular tests can be useful rapid diagnostic tools.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     Nucleic acid amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification assays (NAA) are used to amplify the quantity of M. tuberculosis DNA in diagnostic specimens where organisms may be present in amounts too small to be seen by routine staining techniques. These techniques are sensitive for rapid detection of M. tuberculosis in a variety of specimens, including blood, sputum, and urine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/81-87\">",
"     81-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two NAA tests were approved by the United States Food and Drug Administration as of 2012, but only for use with sputum or respiratory secretions obtained by bronchoscopy. Of the these tests, the Amplified MTD&reg; test (GenProbe) is approved for AFB smear positive or smear negative specimens; Amplicor&reg; (Roche) is approved only for smear positive samples. Sensitivity of these tests is better in smear-positive samples, and a positive test in the appropriate clinical setting likely represents pulmonary TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary advantage of these tests is that a positive result to establish a diagnosis may be available within 24 hours. The United States Centers for Disease Control and Prevention (CDC) has recently published recommendations for the use of these tests in the diagnosis of TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Nucleic acid amplification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33120436\">",
"    <span class=\"h4\">",
"     GeneXpert assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GeneXpert",
"    <span class=\"nowrap\">",
"     MTB/RIF",
"    </span>",
"    assay is an automated nucleic acid amplification test that can simultaneously identify M. tuberculosis and",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/rifampin-rifampicin-drug-information?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance. Among 547 patients with suspected extrapulmonary TB in India and 1068 patients in Europe, the sensitivity and specificity of the Xpert assay were 81 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. The sensitivity was high (63 to 100 percent) for the majority of specimen types [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/91\">",
"     91",
"    </a>",
"    ]. Sensitivity for cerebrospinal fluid is variable (29 to 85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link&amp;anchor=H4856396#H4856396\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Xpert MTB/RIF assay'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H906587244\">",
"    <span class=\"h4\">",
"     Other molecular tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many hospital and clinical laboratories offer nucleic acid amplification testing for M. tuberculosis complex using molecular methods (eg, polymerase chain reaction [PCR]) not been approved by the FDA but validated internally within the testing laboratory according to a written protocol. These &ldquo;in-house&rdquo; tests generally offer high specificity and if positive may be useful in supporting a clinical diagnosis of TB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the approach to antimicrobial therapy for treatment of miliary tuberculosis (TB) is the same as for pulmonary TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/93\">",
"     93",
"    </a>",
"    ]. This approach is based upon retrospective review of a relatively small number of patients with extrapulmonary TB, since extrapulmonary TB is much less common than pulmonary TB. While the data suggest that this approach is successful, individualization of regimens may be warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Modifications to the standard drug regimen may be warranted in the setting of drug-resistant TB. In addition, longer duration of therapy may be warranted for children, immunocompromised hosts, patients with a large organism burden, and patients with a slow microbiologic or clinical response. Longer duration of therapy is also warranted for patients with disease involving the central nervous system (CNS), some patients with bone or joint disease and some cases of lymphadenitis (a site of early relapse in anecdotal reports) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/94\">",
"     94",
"    </a>",
"    ]. Depending on the site(s) and scope of disease, surgical intervention may be needed for diagnostic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapeutic management.",
"   </p>",
"   <p>",
"    Data on the role of corticosteroids in patients with miliary TB are limited; results of case reports and small clinical series using corticosteroids in miliary TB are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/27\">",
"     27",
"    </a>",
"    ]. In some circumstances corticosteroids are warranted for treatment of TB involving the CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/95\">",
"     95",
"    </a>",
"    ] or pericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link&amp;anchor=H30#H30\">",
"     \"Central nervous system tuberculosis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course and outcomes of miliary tuberculosis (TB) have improved markedly between the pre-antibiotic and post-antibiotic eras [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/29,97\">",
"     29,97",
"    </a>",
"    ]. In the United States Veteran's Administration study of miliary TB (excluding meningitis), the attributable mortality dropped successively (from nearly 100 percent) with the introduction of each new drug. Mortality dropped with the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    (to 47 percent), with streptomycin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=see_link\">",
"     para-aminosalicylic acid",
"    </a>",
"    (to 18 percent), and with isoniazid-based combination therapy (to 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/97\">",
"     97",
"    </a>",
"    ]. Subsequently, two large series noted mortality of approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These studies included relatively diverse populations with a range of underlying diseases and did not exclude meningeal TB. Since the introduction of isoniazid-based therapy, case series have documented shorter duration of fever and more rapid clinical and radiographic improvement. In one study, the median time to defervescence was seven days (range 1 to 55 days); 76 percent of patients were afebrile within 14 days of the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors that contribute to survival in miliary TB are difficult to assess, since the literature is generally limited to retrospective case and includes patients with variable clinical and laboratory presentations. However, central nervous system (CNS) disease appears to be an independent predictor of mortality in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/2,3,97\">",
"     2,3,97",
"    </a>",
"    ]. Pancytopenia or lymphopenia were poor prognostic indicators in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/1,54\">",
"     1,54",
"    </a>",
"    ]. Age, late presentation, serious underlying disease, and a non-reactive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    are cited in other studies as predictors of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miliary tuberculosis (TB) can be prevented by treatment of latent TB infection. In addition, childhood administration of BCG in endemic areas reduces the incidence of miliary TB. A large meta-analysis found a 78 percent protective effect of the vaccine against miliary TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/21/20826/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=see_link\">",
"     \"BCG vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6857598\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miliary tuberculosis (TB) refers to clinical disease resulting from the hematogenous dissemination of Mycobacterium tuberculosis. Miliary TB can arise as a result of progressive primary infection or via reactivation of a latent focus with subsequent spread. The clinical presentation of miliary TB is highly variable; manifestations can be acute but are more likely to be subacute or chronic. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute disease may be fulminant, including multiorgan system failure, a syndrome of septic shock and acute respiratory distress syndrome (ARDS). Patients with subacute or chronic disease may present with failure to thrive, fever of unknown origin, or dysfunction of one or more organ systems. The most common extrapulmonary sites of disease include the lymphatic system, bones and joints, and the liver. The clinical approach to evaluation of TB at extrapulmonary sites is discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common laboratory abnormalities include anemia and other hematologic findings. Other laboratory abnormalities may include elevated acute phase reactants, hyponatremia, hypercalcemia and sterile pyuria. The classic chest radiograph appearance is a faint, reticulonodular infiltrate distributed fairly uniformly throughout the lungs (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63302 \" href=\"UTD.htm?30/61/31698\">",
"       image 1",
"      </a>",
"      ). Other chest radiograph abnormalities include pleural reactions, hilar or mediastinal adenopathy, interstitial or alveolar infiltrates, or cavities. Computed tomography of the chest is more sensitive for evaluation of miliary TB than plain chest radiography (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiographic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical evaluation begins with a thorough history and physical examination. In general an evaluation for pulmonary disease is warranted in all patients in whom disseminated TB is suspected. In addition, mycobacterial blood culture should be performed. In regions where available, molecular tests can be useful rapid diagnostic tools. (See",
"      <a class=\"local\" href=\"#H13124464\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The subsequent diagnostic evaluation should be tailored to localizing signs or symptoms of disease involvement. Patients with neurologic signs or symptoms should undergo neuroimaging and lumbar puncture (if feasible). In the setting of pleural effusion, pericardial effusion or ascites, fluid should be obtained for evaluation and a biopsy strongly considered. Radiographic imaging of the involved site(s) may be warranted for patients with symptoms referable to the gastrointestinal tract, genitourinary tract,",
"      <span class=\"nowrap\">",
"       bones/joints",
"      </span>",
"      or lymph nodes. Suspected genitourinary disease should prompt urine AFB culture. Depending on the involved site(s), tissue biopsy may be required to establish a definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H13124464\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy specimens allow for both histopathologic examination and acid fast culture. Biopsy sites with relatively good yield include the pleura, liver, bone marrow, lymph nodes and transbronchial biopsies; the yield is likely to be increased in the setting of associated clinical or laboratory abnormalities. Histopathology typically demonstrates granulomatous inflammation. Tuberculous granulomas characteristically contain epithelioid macrophages, Langhans giant cells, and lymphocytes, and the centers often have characteristic caseation (\"cheese-like\") necrosis. (See",
"      <a class=\"local\" href=\"#H13124590\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the approach to antimicrobial therapy for treatment of miliary TB is the same as for pulmonary TB, although modifications may be warranted in the setting of drug-resistant TB. In addition, longer duration of therapy may be warranted for children, immunocompromised hosts, patients with a large organism burden, and patients with a slow microbiologic or clinical response. Longer duration of therapy is also warranted for patients with disease involving the central nervous system, some patients with bone or joint disease, and some cases of lymphadenitis. Surgical intervention may be needed for diagnostic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      therapeutic management in some cases. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/1\">",
"      Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 1990; 89:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/2\">",
"      Kim JH, Langston AA, Gallis HA. Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome. Rev Infect Dis 1990; 12:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/3\">",
"      Gelb AF, Leffler C, Brewin A, et al. Miliary tuberculosis. Am Rev Respir Dis 1973; 108:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/4\">",
"      Munt PW. Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults. Medicine (Baltimore) 1972; 51:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/5\">",
"      Proudfoot AT, Akhtar AJ, Douglas AC, Horne NW. Miliary tuberculosis in adults. Br Med J 1969; 2:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/6\">",
"      BIEHL JP. Miliary tuberculosis; a review of sixty-eight adult patients admitted to a municipal general hospital. Am Rev Tuberc 1958; 77:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/7\">",
"      Sydow M, Schauer A, Crozier TA, Burchardi H. Multiple organ failure in generalized disseminated tuberculosis. Respir Med 1992; 86:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/8\">",
"      Ahuja SS, Ahuja SK, Phelps KR, et al. Hemodynamic confirmation of septic shock in disseminated tuberculosis. Crit Care Med 1992; 20:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/9\">",
"      Piqueras AR, Marruecos L, Artigas A, Rodriguez C. Miliary tuberculosis and adult respiratory distress syndrome. Intensive Care Med 1987; 13:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/10\">",
"      Mohan A, Sharma SK, Pande JN. Acute respiratory distress syndrome (ARDS) in miliary tuberculosis: a twelve year experience. Indian J Chest Dis Allied Sci 1996; 38:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/11\">",
"      Asada Y, Hayashi T, Sumiyoshi A, et al. Miliary tuberculosis presenting as fever and jaundice with hepatic failure. Hum Pathol 1991; 22:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/12\">",
"      Harvey C, Eykyn S, Davidson C. Rigors in tuberculosis. Postgrad Med J 1993; 69:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/13\">",
"      Lowry KJ, Stephan KT, Davis CE. Miliary tuberculosis presenting with rigors and developing unusual cutaneous manifestations. Cutis 1999; 64:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/14\">",
"      Rieder HL, Kelly GD, Bloch AB, et al. Tuberculosis diagnosed at death in the United States. Chest 1991; 100:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/15\">",
"      Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002; 6:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/16\">",
"      Heap MJ, Bion JF, Hunter KR. Miliary tuberculosis and the adult respiratory distress syndrome. Respir Med 1989; 83:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/17\">",
"      Lintin SN, Isaac PA. Miliary tuberculosis presenting as adult respiratory distress syndrome. Intensive Care Med 1988; 14:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/18\">",
"      Murray HW, Tuazon CU, Kirmani N, Sheagren JN. The adult respiratory distress syndrome associated with miliary tuberculosis. Chest 1978; 73:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/19\">",
"      Dyer RA, Chappell WA, Potgieter PD. Adult respiratory distress syndrome associated with miliary tuberculosis. Crit Care Med 1985; 13:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/20\">",
"      Heffner JE, Strange C, Sahn SA. The impact of respiratory failure on the diagnosis of tuberculosis. Arch Intern Med 1988; 148:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/21\">",
"      Corbella X, Carratala J, Rufi G, Gudiol F. Unusual manifestations of miliary tuberculosis: cutaneous lesions, phalanx osteomyelitis, and paradoxical expansion of tenosynovitis. Clin Infect Dis 1993; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/22\">",
"      Teo HE, Peh WC. Skeletal tuberculosis in children. Pediatr Radiol 2004; 34:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/23\">",
"      Vohra R, Kang HS, Dogra S, et al. Tuberculous osteomyelitis. J Bone Joint Surg Br 1997; 79:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/24\">",
"      Brusko G, Melvin WS, Fromkes JJ, Ellison EC. Pancreatic tuberculosis. Am Surg 1995; 61:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/25\">",
"      Gowrinath K, Ashok S, Thanasekaran V, Rao KR. Tuberculous cholecystitis. Int J Tuberc Lung Dis 1997; 1:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/26\">",
"      Ramesh J, Banait GS, Ormerod LP. Abdominal tuberculosis in a district general hospital: a retrospective review of 86 cases. QJM 2008; 101:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/27\">",
"      Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005; 5:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/28\">",
"      Hussain W, Mutimer D, Harrison R, et al. Fulminant hepatic failure caused by tuberculosis. Gut 1995; 36:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/29\">",
"      Slavin RE, Walsh TJ, Pollack AD. Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras. Medicine (Baltimore) 1980; 59:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/30\">",
"      Baker CA, Cartwright CP, Williams DN, et al. Early detection of central nervous system tuberculosis with the gen-probe nucleic Acid amplification assay: utility in an inner city hospital. Clin Infect Dis 2002; 35:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/31\">",
"      Caws M, Wilson SM, Clough C, Drobniewski F. Role of IS6110-targeted PCR, culture, biochemical, clinical, and immunological criteria for diagnosis of tuberculous meningitis. J Clin Microbiol 2000; 38:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/32\">",
"      Brienze VM, Pereira FJ, Liso E, et al. Low sensitivity of polymerase chain reaction for diagnosis of tuberculous meningitis in southeastern Brazil. Rev Soc Bras Med Trop 2001; 34:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/33\">",
"      Namavar Jahromi B, Parsanezhad ME, Ghane-Shirazi R. Female genital tuberculosis and infertility. Int J Gynaecol Obstet 2001; 75:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/34\">",
"      Sharma JB, Roy KK, Pushparaj M, et al. Laparoscopic findings in female genital tuberculosis. Arch Gynecol Obstet 2008; 278:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/35\">",
"      Lee IK, Yang WC, Liu JW. Scrotal tuberculosis in adult patients: a 10-year clinical experience. Am J Trop Med Hyg 2007; 77:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/36\">",
"      Lam KY, Lo CY. A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis. Clin Endocrinol (Oxf) 2001; 54:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/37\">",
"      Barnes DJ, Naraqi S, Temu P, Turtle JR. Adrenal function in patients with active tuberculosis. Thorax 1989; 44:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/38\">",
"      CHAPMAN CB, WHORTON CM. Acute generalized miliary tuberculosis in adults. N Engl J Med 1946; 235:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/39\">",
"      Wallis PJ, Branfoot AC, Emerson PA. Sudden death due to myocardial tuberculosis. Thorax 1984; 39:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/40\">",
"      Cope AP, Heber M, Wilkins EG. Valvular tuberculous endocarditis: a case report and review of the literature. J Infect 1990; 21:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/41\">",
"      Reuter H, Burgess LJ, Doubell AF. Role of chest radiography in diagnosing patients with tuberculous pericarditis. Cardiovasc J S Afr 2005; 16:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/42\">",
"      Rooney JJ, Crocco JA, Lyons HA. Tuberculous pericarditis. Ann Intern Med 1970; 72:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/43\">",
"      Cegielski JP, Lwakatare J, Dukes CS, et al. Tuberculous pericarditis in Tanzanian patients with and without HIV infection. Tuber Lung Dis 1994; 75:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/44\">",
"      Nardell EA, Fan D, Shepard JA, Mark EJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 22-2004. A 30-year-old woman with a pericardial effusion. N Engl J Med 2004; 351:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/45\">",
"      Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation 2005; 112:3608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/46\">",
"      Felson B, Akers PV, Hall GS, et al. Mycotic tuberculous aneurysm of the thoracic aorta. JAMA 1977; 237:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/47\">",
"      Rietbroek RC, Dahlmans RP, Smedts F, et al. Tuberculosis cutis miliaris disseminata as a manifestation of miliary tuberculosis: literature review and report of a case of recurrent skin lesions. Rev Infect Dis 1991; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/48\">",
"      Daikos GL, Uttamchandani RB, Tuda C, et al. Disseminated miliary tuberculosis of the skin in patients with AIDS: report of four cases. Clin Infect Dis 1998; 27:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/49\">",
"      Johnson AW, Mokuolu OA, Ogan O. Tuberculous laryngitis in a Nigerian child. Ann Trop Paediatr 1993; 13:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/50\">",
"      Vomero E, Ratner SJ. Diagnosis of miliary tuberculosis by examination of middle ear discharge. Arch Otolaryngol Head Neck Surg 1988; 114:1029.",
"     </a>",
"    </li>",
"    <li>",
"     Basgoz N, Swartz MN. Infections of the thyroid gland. In: The Thyroid: A Fundamental and Clinical Text, Braverman LE, Utiger RD (Eds), Lippincott-Raven, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/52\">",
"      MILDER E, OXENHORN S, SCHLECKER A, et al. A case of miliary tuberculosis simulating acute blastic leukemia. JAMA 1961; 177:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/53\">",
"      TWOMEY JJ, LEAVELL BS. LEUKEMOID REACTIONS TO TUBERCULOSIS. Arch Intern Med 1965; 116:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/54\">",
"      Hunt BJ, Andrews V, Pettingale KW. The significance of pancytopenia in miliary tuberculosis. Postgrad Med J 1987; 63:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/55\">",
"      Campo E, Condom E, Miro MJ, et al. Tuberculosis-associated hemophagocytic syndrome. A systemic process. Cancer 1986; 58:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/56\">",
"      Isaacs RD, Nicholson GI, Holdaway IM. Miliary tuberculosis with hypercalcaemia and raised vitamin D concentrations. Thorax 1987; 42:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/57\">",
"      Felson B. A new look at pattern recognition of diffuse pulmonary disease. AJR Am J Roentgenol 1979; 133:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/58\">",
"      Felson B. The roentgen diagnosis of disseminated pulmonary alveolar diseases. Semin Roentgenol 1967; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/59\">",
"      Kwong JS, Carignan S, Kang EY, et al. Miliary tuberculosis. Diagnostic accuracy of chest radiography. Chest 1996; 110:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/60\">",
"      Optican RJ, Ost A, Ravin CE. High-resolution computed tomography in the diagnosis of miliary tuberculosis. Chest 1992; 102:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/61\">",
"      Voloudaki AE, Tritou IN, Magkanas EG, et al. HRCT in miliary lung disease. Acta Radiol 1999; 40:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/62\">",
"      Lee KS, Kim TS, Han J, et al. Diffuse micronodular lung disease: HRCT and pathologic findings. J Comput Assist Tomogr 1999; 23:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/63\">",
"      Kao CH, Wang SJ, Liao SQ, et al. Usefulness of gallium-67-citrate scans in patients with acute disseminated tuberculosis and comparison with chest x-rays. J Nucl Med 1993; 34:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/64\">",
"      Brauner M, Buffard MD, Jeantils V, et al. Sonography and computed tomography of macroscopic tuberculosis of the liver. J Clin Ultrasound 1989; 17:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/65\">",
"      Shinnick TM, Good RC. Diagnostic mycobacteriology laboratory practices. Clin Infect Dis 1995; 21:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/66\">",
"      Hanna BA, Walters SB, Bonk SJ, Tick LJ. Recovery of mycobacteria from blood in mycobacteria growth indicator tube and Lowenstein-Jensen slant after lysis-centrifugation. J Clin Microbiol 1995; 33:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/67\">",
"      Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/68\">",
"      Munseri PJ, Talbot EA, Bakari M, et al. The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania. Scand J Infect Dis 2011; 43:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/69\">",
"      Steingart KR, Henry M, Laal S, et al. A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax 2007; 62:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/70\">",
"      Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis. PLoS Med 2011; 8:e1001074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/71\">",
"      Steingart KR, Flores LL, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med 2011; 8:e1001062.",
"     </a>",
"    </li>",
"    <li>",
"     file://whqlibdoc.who.int/publications/2011/9789241502054_eng.pdf (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/73\">",
"      Mert A, Bilir M, Tabak F, et al. Miliary tuberculosis: clinical manifestations, diagnosis and outcome in 38 adults. Respirology 2001; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/74\">",
"      Willcox PA, Potgieter PD, Bateman ED, Benatar SR. Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope. Thorax 1986; 41:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/75\">",
"      Pant K, Chawla R, Mann PS, Jaggi OP. Fiberbronchoscopy in smear-negative miliary tuberculosis. Chest 1989; 95:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/76\">",
"      Strumpf IJ, Tsang AY, Sayre JW. Re-evaluation of sputum staining for the diagnosis of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/77\">",
"      Stender H, Mollerup TA, Lund K, et al. Direct detection and identification of Mycobacterium tuberculosis in smear-positive sputum samples by fluorescence in situ hybridization (FISH) using peptide nucleic acid (PNA) probes. Int J Tuberc Lung Dis 1999; 3:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/78\">",
"      Roggenkamp A, Hornef MW, Masch A, et al. Comparison of MB/BacT and BACTEC 460 TB systems for recovery of mycobacteria in a routine diagnostic laboratory. J Clin Microbiol 1999; 37:3711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/79\">",
"      Crump JA, Ramadhani HO, Morrissey AB, et al. Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study. Clin Infect Dis 2012; 55:242.",
"     </a>",
"    </li>",
"    <li>",
"     Pathology of Tuberculosis. The Internet Pathology Laboratory for Medical Education. Available at: file://www-medlib.med.utah.edu/WebPath/TUTORIAL/MTB/MTB.html (Accessed on March 23, 2006).",
"    </li>",
"    <li>",
"     Shinnick TM, Jonas V. Molecular approaches to the diagnosis of tuberculosis. In: Tuberculosis: pathogenesis, protection and control, Bloom BR (Ed), American Society of Microbiology Press, Washington DC 1994. p.517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/82\">",
"      Clarridge JE 3rd, Shawar RM, Shinnick TM, Plikaytis BB. Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory. J Clin Microbiol 1993; 31:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/83\">",
"      Kaneko K, Onodera O, Miyatake T, Tsuji S. Rapid diagnosis of tuberculous meningitis by polymerase chain reaction (PCR). Neurology 1990; 40:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/84\">",
"      Akcan Y, Tuncer S, Hayran M, et al. PCR on disseminated tuberculosis in bone marrow and liver biopsy specimens: correlation to histopathological and clinical diagnosis. Scand J Infect Dis 1997; 29:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/85\">",
"      Folgueira L, Delgado R, Palenque E, et al. Rapid diagnosis of Mycobacterium tuberculosis bacteremia by PCR. J Clin Microbiol 1996; 34:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/86\">",
"      Schluger NW, Rom WN. The polymerase chain reaction in the diagnosis and evaluation of pulmonary infections. Am J Respir Crit Care Med 1995; 152:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/87\">",
"      Aceti A, Zanetti S, Mura MS, et al. Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay. Thorax 1999; 54:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/88\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/89\">",
"      Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/90\">",
"      Centers for Disease Control and Prevention (CDC). Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006. MMWR Morb Mortal Wkly Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/91\">",
"      Vadwai V, Boehme C, Nabeta P, et al. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 2011; 49:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/92\">",
"      Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012; 40:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/93\">",
"      American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986; 134:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/94\">",
"      Oktay MF, Topcu I, Senyigit A, et al. Follow-up results in tuberculous cervical lymphadenitis. J Laryngol Otol 2006; 120:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/95\">",
"      Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis 1997; 25:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/96\">",
"      Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/97\">",
"      FALK A. U. S. VETERANS ADMINISTRATION-ARMED FORCES COOPERATIVE STUDY ON THE CHEMOTHERAPY OF TUBERCULOSIS.13. TUBERCULOUS MENINGITIS IN ADULTS, WITH SPECIAL REFERENCE TO SURVIVAL, NEUROLOGIC RESIDUALS, AND WORK STATUS. Am Rev Respir Dis 1965; 91:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/98\">",
"      Sahn SA, Neff TA. Miliary tuberculosis. Am J Med 1974; 56:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/21/20826/abstract/99\">",
"      Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8024 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-791DB7C3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20826=[""].join("\n");
var outline_f20_21_20826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6857598\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7880259\">",
"      Lymphatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7880317\">",
"      Bone and joint disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Central nervous system disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genitourinary and adrenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8444360\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7880479\">",
"      Cutaneous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other organ involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RADIOGRAPHIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13124464\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13124472\">",
"      Diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13124651\">",
"      - Tuberculin skin test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Acid fast smear and culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13124590\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Molecular tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nucleic acid amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H33120436\">",
"      GeneXpert assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H906587244\">",
"      Other molecular tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6857598\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8024|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/61/31698\" title=\"diagnostic image 1\">",
"      Miliary tuberculosis CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/49/33553\" title=\"diagnostic image 2\">",
"      Miliary TB high resolution CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8024|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/6/7269\" title=\"picture 1\">",
"      Millet seeds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14631\" title=\"picture 2\">",
"      Miliary lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8024|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/31/37372\" title=\"table 1\">",
"      Clinical series of miliary TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29660\" title=\"table 2\">",
"      Symptoms of miliary TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/27/25020\" title=\"table 3\">",
"      Physical signs in miliary TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/63/32764\" title=\"table 4\">",
"      Lab findings in miliary TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/20/30028\" title=\"table 5\">",
"      Ddx miliary infiltrates on CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/31/39420\" title=\"table 6\">",
"      Evaluation for TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/18/5420\" title=\"table 7\">",
"      Positive cultures in miliary TB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=related_link\">",
"      BCG vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21034?source=related_link\">",
"      Cutaneous manifestations of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34150?source=related_link\">",
"      Epidemiology and pathology of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14005?source=related_link\">",
"      Renal disease in tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5767?source=related_link\">",
"      Tuberculosis and the eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43862?source=related_link\">",
"      Tuberculous enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27768?source=related_link\">",
"      Tuberculous lymphadenitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=related_link\">",
"      Tuberculous pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36614?source=related_link\">",
"      Tuberculous peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=related_link\">",
"      Tuberculous pleural effusions in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_21_20827="Indications for TBNA";
var content_f20_21_20827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for transbronchial needle aspiration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mediastinal and/or hilar lymphadenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        To establish a histologic diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        To stage known or suspected bronchogenic carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Endobronchial lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Especially useful in cases of necrotic tumor, hemorrhagic tumor, or to define the line of surgical resection (see text)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrinsic compression of the airway by a peribronchial process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Submucosal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral nodules/masses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow-up of small-cell tumors, lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnosis and/or drainage of mediastinal cysts and/or mediastinal abscesses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20827=[""].join("\n");
var outline_f20_21_20827=null;
var title_f20_21_20828="In vitro activity against Aspergillus fumigatus";
var content_f20_21_20828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    In vitro activity of echinocandins and azoles against Aspergillus fumigatus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mold species",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antifungal agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        MIC or MEC90* mcg/mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        % Resistant",
"       </td>",
"      </tr>",
"      <tr>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        <em>",
"         Aspergillus fumigatus",
"        </em>",
"       </td>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0.008",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        &le;0.008",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MIC: minimum inhibitory concentration; MEC: minimum effective concentration; endpoint for defining in vitro susceptibility of echinocandins against",
"     <em>",
"      Aspergillus",
"     </em>",
"     spp; NA: breakpoints not available.",
"     <br>",
"      * MIC required to inhibit 90 percent of the tested population.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Resistance defined as an MIC of &gt;2 mcg/mL for posaconazole and voriconazole against all",
"       <em>",
"        Aspergillus",
"       </em>",
"       species; non-wild-type strains of",
"       <em>",
"        A. fumigatus",
"       </em>",
"       defined as showing MICs greater than the epidemiologic cut-off of &gt;1 mcg/mL for itraconazole and voriconazole and of&nbsp; &gt;0.5 mcg/mL for posaconazole.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Pfaller MA, Castanhiera M, Messer SA, et al. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011; 69:45.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20828=[""].join("\n");
var outline_f20_21_20828=null;
var title_f20_21_20829="Tumor size lymph node status";
var content_f20_21_20829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor size and lymph node status for women undergoing biopsy after screening mammography: breast cancer surveillance consortium, 1996-2001",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"4\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"11\">",
"        Lymph node status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"2\">",
"        Lymph nodes not examined",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"2\">",
"        Negative",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"6\">",
"        No. of positive LN's",
"       </td>",
"       <td class=\"subtitle2\" rowspan=\"3\">",
"        Total no.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        1 to 3",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        4 to 9",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        &ge;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        No.",
"       </td>",
"       <td class=\"subtitle3\">",
"        Row percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        No.",
"       </td>",
"       <td class=\"subtitle3\">",
"        Row percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        No.",
"       </td>",
"       <td class=\"subtitle3\">",
"        Row percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        No.",
"       </td>",
"       <td class=\"subtitle3\">",
"        Row percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        No.",
"       </td>",
"       <td class=\"subtitle3\">",
"        Row percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Total",
"       </td>",
"       <td>",
"        639",
"       </td>",
"       <td>",
"        9.4",
"       </td>",
"       <td>",
"        4828",
"       </td>",
"       <td>",
"        71.0",
"       </td>",
"       <td>",
"        937",
"       </td>",
"       <td>",
"        13.8",
"       </td>",
"       <td>",
"        267",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        6804",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        Tumor size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-10 mm",
"       </td>",
"       <td>",
"        315",
"       </td>",
"       <td>",
"        13.3",
"       </td>",
"       <td>",
"        1882",
"       </td>",
"       <td>",
"        79.6",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        2365 (100 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11-20 mm",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        7.0",
"       </td>",
"       <td>",
"        1760",
"       </td>",
"       <td>",
"        72.8",
"       </td>",
"       <td>",
"        394",
"       </td>",
"       <td>",
"        16.3",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        2419 (100 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        21-50 mm",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        675",
"       </td>",
"       <td>",
"        55.6",
"       </td>",
"       <td>",
"        305",
"       </td>",
"       <td>",
"        25.1",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        10.1",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        1215 (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;50",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        38.2",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        23.2",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        17.4",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"       <td>",
"        207",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unknown*",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        15.2",
"       </td>",
"       <td>",
"        432",
"       </td>",
"       <td>",
"        72.2",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        598",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LN: Lymph nodes.",
"     <br>",
"      * Unknown tumor size includes mammography diagnoses only, Paget disease, and pathologically invasive carcinoma, all with size not stated. Excluded from the table were 339 women who had lymph node examinations, including 10 women with an unknown number of positive lymph nodes and 329 women with unknown status of the lymph nodes examined.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Weaver, D, Rosenberg, R, Barlow, W, et al. Pathologic findings from the breast cancer surveillance consortium. CANCER 2006; 106:732. Copyright &copy;2006 the American Cancer Society. The material is reproduced with the permission of Wiley-Liss, Inc., a subsidiary of John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20829=[""].join("\n");
var outline_f20_21_20829=null;
var title_f20_21_20830="Pneumatosis intestinalis of the colon on plain film";
var content_f20_21_20830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumatosis intestinalis of the colon on plain film",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 225px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A plain film of the abdomen demonstrates air within the wall of the ascending colon (arrow). This can be seen in ischemic bowel, but may also occur after colonoscopy or surgical anastomoses, and in patients taking corticosteroids or with HIV infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20830=[""].join("\n");
var outline_f20_21_20830=null;
var title_f20_21_20831="Preeclampsia immunofluorescence microscopy";
var content_f20_21_20831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    IgM deposition in preeclampsia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in preeclampsia showing diffuse IgM deposition. This represents nonspecific entrapment of larger proteins in the more permeable glomerular capillary wall, rather than the formation of discrete immune complexes. There is, for example, generally no deposition of IgG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_21_20831=[""].join("\n");
var outline_f20_21_20831=null;
